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PHARMACOGENETIC TESTING IN OUTPATIENT MENTAL HEALTH CLINICS 
Tammie Gainey 
Dr. Tina L. Bloom, Dissertation Supervisor 
ABSTRACT 
 
The purpose of this study was to evaluate mental health clinicians’ perceived 
knowledge regarding pharmacogenetic testing; their attitude, receptivity towards, and 
confidence in pharmacogenetic testing; and how pharmacogenetic testing is being 
implemented to support decision making in outpatient clinics. This study was guided by 
Rogers’ Diffusion of Innovation (DOI) Theory. An exhausted literature search was 
conducted to find studies on mental health clinicians’ knowledge, perceived attitudes, and 
implementation of pharmacogenetic testing.  The subject population included 28 mental 
health clinicians who are actively utilizing pharmacogenetic testing in outpatient mental 
health clinics. Participants responded to semi-structured open-ended prompts regarding 
knowledge, perceptions and implementation of pharmacogenetic testing in mental health 
outpatient clinics. Data were analyzed using a qualitative descriptive approach. Five 
relevant themes emerged related to the perceptions of pharmacogenetic testing, impact on 
clinical decision-making, associated concerns of pharmacogenetic testing, knowledge 
gaps among clinicians, and policy challenges.  Overall, clinicians perceived 
pharmacogenetic testing beneficial to guide dosing and medication selection to decrease 
the risk of side effects and increase tolerability of psychotropic medications. This study 
will lead to future research to support shared decision-making around pharmacogenetic 
testing, medication adherence and tolerability, and setting guidelines for pharmacogenetic 
testing in mental health clinics. 
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Chapter I 
Introduction 
Approximately 100,000 deaths occur annually in the U.S. due to adverse effects 
from medications (Davies, Green, Taylor, Williamson, Mottram, & Pirmohamed, 2009; 
Eichelbaum, Ingelman-Sundberg, & Evans, 2006). Pharmacogenetics is the phenomenon 
where an individual’s gene variations influence drug response and side effects (Lohaff & 
Ferraro, 2010). Pharmacogenetic testing focuses on a single gene and drug interaction 
and supports the adoption of precision medicine in mental health (Hess, Fonseca, Scott, 
& Fagerness, 2015; Schosser & Kasper, 2009).  Precision medicine is defined as 
treatments tailored to meet individual’s needs using genetic information (Jameson & 
Longo, 2015). Clinicians are increasingly using such testing to guide medication 
selection and dosing to improve patient outcomes (National Institutes of Health: National 
Human Genome Research Institute, 2014).  
Although pharmacogenetic testing has been used in oncology, cardiology and 
pain management, it is only beginning to be used in outpatient mental health settings. 
Pharmacogenetic testing has the potential to identify genetic differences in medication 
response and guide clinical decision making. This study begins to address the gap 
regarding knowledge, attitudes, and practices of mental health clinicians regarding 
pharmacogenetic testing, an intervention with significant future implications for 
treatment decision-making. 
The tolerability and effectiveness of psychotropic medications is highly variable. 
Approximately 60% of patients do not respond completely to antidepressants and 30% do 
not respond at all (Crisafulli et al., 2011). Similarly, 74% of patients being treated for 
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Schizophrenia discontinued medications due to side effects and ineffectiveness 
(Lieberman et al., 2005). Due to genetic factors, patients may vary widely in how they 
respond to mental health medications. For example, genetic factors contribute to 
approximately 50% of antidepressant responses (Crissafull et al., 2011). Patients 
metabolize antidepressants at vastly different rates and can experience different responses 
to the same drug (Dalen, Dahl, Ruiz, Nordin, & Bertilsson, 1998; Lohaff & Ferraro, 
2010). 
 According to the Food and Drug Administration, there are more than 100 
prescription medications that have pharmacogenetic information while approximately 
30% are psychotropic medications (Food and Drug Adminstration, 2015; Malik, Caley, & 
Azeem, 2014). A large percentage of psychotropic medications are metabolized by the 
CYP450 enzyme system: 1A2, 2B6, 2C9, 2D6, and 3A4 (Black, O’Kane, & Mrazek, 
2007). A patient’s metabolizer status can be determined according to the enzyme. 
Patients may be ultra-rapid metabolizers, extensive metabolizers, intermediate 
metabolizers, or poor metabolizers of a certain medication – requiring very different 
doses or perhaps different medications-- depending on their genetic expression of a 
particular enzyme. An ultra-rapid metabolizer refers to someone whose metabolic 
capacity is greater than normal and will likely require a higher dosage of medications to 
obtain the same response as someone who is an extensive metabolizer. An extensive 
metabolizer represents a person with a normal metabolic capacity who requires standard 
doses of medications to obtain a therapeutic response. An intermediate metabolizer refers 
to a person with a decreased metabolic capacity requiring lower doses of medications to 
decrease the risk of side effects and increase efficacy of medications. A poor metabolizer 
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represents an absent metabolic capacity, which at standard doses patients are at increased 
risk of accumulation of medication, side effects and decreased efficacy of the medication 
(Black et al., 2007). 
 Among patients with mental illness, side effects and decreased efficacy of 
antidepressants and antipsychotics result in substandard outcomes, medication 
nonadherence, and loss of confidence in medications (Mulsant & Lenze, 2014). 
Pharmacogenetic testing may provide safer and more effective treatments among patients 
with mental illness (Walden et al., 2015). The utilization of pharmacogenetic testing in 
medication selection and dosing has resulted in patients with earlier remission in 
treatment (Smits, Smits, Schouten, Peeters, & Prins, 2007).   
 Many mental health clinicians report positive attitudes towards pharmacogenetic 
testing (Haga Burke, Ginsburg, Mills, & Agans, 2012; Lankree, et al., 2014; Mrazek et 
al., 2007). Large majorities of psychiatrists and general practitioners surveyed in research 
believe pharmacogenetic testing would be beneficial to guide medication selection among 
patients with mental illness (Thompson, Hamilton, & Hippman, 2015) and will become a 
standard of care (Walden et al., 2015). The use of pharmacogenetic testing has doubled 
from 2012 to 2015 and clinicians believe that it will continue to rapidly increase over the 
next few years (Walden et al., 2015). 
Research consistently shows clinicians typically report limited knowledge or 
understanding of pharmacogenetic testing (Dodson 2011; Kadafour, Haugh, Posin, 
Kayser, & Shin, 2009; Hoop, Lapid, Pualson, and Roberts, 2010, Dodson & Lewallen, 
2011, Tamaoiki, Gushima, & Tsutani, 2007).  Many also report concerns regarding cost 
effectiveness, ethical concerns, lack of medication adherence, patient acceptability, time 
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frame of test, and inadequate evidence-based outcomes (Dorfman, Trinidad, Morales, 
Howlett, Burke, & Woodahl, 2014; Ghaddar, Cascorbi, & Zgheib, 2012; Haga, Tindall, 
& O’Daniel, 2012; Schnoll & Schields, 2011; Squassina et al., 2010).  No guidelines 
exist to guide mental health clinicians in the use of pharmacogenetic testing in clinical 
practice (Quinones et al., 2014) and very little is understood about how mental health 
clinicians understand and implement such tests in outpatient settings.   
 Rogers’ Diffusion of Innovation (DOI) theory (Rogers, 2003) guides the proposed 
study.  DOI theory suggests innovation adoption involves five stages: knowledge, 
persuasion, decision, implementation, and confirmation. This study will focus on mental 
health clinicians’ knowledge, beliefs and opinions, decision making, and the 
implementation of pharmacogenetic testing in mental health clinics. Identifying how 
pharmacogenetic testing is being implemented in current practice and how it affects 
treatment decision making may have a positive effect on reducing unwarranted adverse 
effects while enhancing the effectiveness and tolerability of psychotropic medications.  
To assist mental health clinicians in understanding pharmacogenetics, the knowledge and 
beliefs of pharmacogenetic testing among mental health clinicians must be identified.  
 This study will contribute to the literature by exploring the knowledge, beliefs, 
and implementation strategies of pharmacogenetic testing among mental health clinicians 
in outpatient mental health clinics. Qualitative analysis can help identify knowledge gaps 
and reveal challenges in implementation of pharmacogenetic testing. This study will use 
a qualitative descriptive approach to address this gap and describe mental health 
clinicians’ adoption of pharmacogenetic testing and how such testing is being 
implemented into clinical workflow to support clinical decision making.  
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 A greater understanding of the utilization of pharmacogenetic testing in 
medication management may reduce serious adverse effects and polypharmacy which are 
common in mental health prescribing (Laje, 2013). Pharmacogenetic testing can 
determine if patients are experiencing multiple side effects or an ineffective dose 
response due to their metabolizer status (Kung & Xiaofan, 2010). Pharmacogenetic-
guided treatment can improve the accuracy of medication responses and decrease the risk 
of side effects (Mrazek et al., 2010). 
This research has important implications for future advanced nursing practice and 
precision medicine around pharmacogenetic testing and medications (e.g., examining 
patient perspectives and testing influence on outcomes such as decision conflict, 
medication adherence, and illness trajectories) and intervention development (e.g., patient 
decision aids) among patients with mental illness (Substance Abuse and Mental Health 
Services Administration, 2010). Disseminating information about knowledge gaps 
regarding pharmacogenetic testing among mental health clinicians may aid in the 
implementation of pharmacogenetics in nursing and medical curricula. In addition, this 
knowledge may assist in the development of continuing education for practicing mental 
health clinicians.  
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Chapter II 
Review of Related Literature 
 This chapter reviews the history of pharmacogenetic testing and prescribing in 
mental health. In addition, this chapter reviews previous literature and describes search 
methods and results. A review of mental health clinicians’ knowledge, perceived 
attitudes, and implementation of pharmacogenetic testing is included in this section. 
Lastly, this chapter describes Roger’s Diffusion of Innovation Model and how this model 
will guide the study. 
History of Pharmacogenetic Testing in Mental Health  
 In 2003, the Human Genome Project was successful in mapping the first human 
genome (National Institute of General Medical Sciences, 2013). Genome is defined as the 
complete set of instructions found in a cell (National Institutes of Health U.S. National 
Library of Medicine, 2017). Pharmacogenetics is how a person’s genome influences the 
metabolism of certain medications (National Institute of General Medical Sciences, 
2013).   
 There are more than 3 billion DNA base pairs in the copy of a person’s genome 
(National Institutes of Health U.S. National Library of Medicine, 2017). A person’s DNA 
determines how cytochrome P450 enzymes affect medication metabolism. Although 
there are over 50 variations of enzymes, approximately 90% of medication metabolism is 
affected by only six CYP450 enzymes (Lynch & Price, 2007).  A large percentage of 
psychotropic medications are metabolized by the following CYP450 enzymes: CYP1A2, 
CYP2B6, CYP2C9, CYP2D6, and CYP3A4 (Black, O’Kane, & Mrazek, 2007).  
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Among the CYP450 enzymes, CYP2D6 and CYP2C19 are involved in many 
antidepressants and antipsychotics (PharmGKB, 2015). Researchers found in a 
restrospective study that hospitalized psychiatric patients with one or two nonfunctioning 
CYP2D6 alleles prescribed antidepressants or antipsychotics were more likely to have 
medication changes (Mulder et al., 2005). Alleles are one of two versions of a gene that 
affects inherited traits (Quigley, 2015). Each person inherits one allele from each parent 
which means that there are two alleles for each gene (Quigley, 2015). Patients with 
nonfunctioning CYP2D6 or CYP2C19 enzymes have resulted in longer hospitalizations 
(Kropp, Lichtinghagen, Winterstein, Schlimme, & Schneider, 2006).  In another 
retrospective study, researchers found patients who were poor metabolizers of CYP2D6 
resulted in longer hospitalizations if taking psychotropics dependent on the enzyme 
CYP2D6 for metabolism (Chou et al., 2000). Patients identified as ultra-rapid 
metabolizers were found to have lower blood levels of tricyclic antidepressants resulting 
in nonadherence to medications (Kootstra-Ros et al., 2006). Variants in genes may affect 
the efficacy and toxicity of medications.  
Although traditional treatment focuses on a trial and error approach, 
pharmacogenetic testing may be used to guide treatment decisions regarding medication 
selection and dosing to predict and reduce adverse reactions and efficacy of medications 
(Dahl & Sjoqvist, 2000; Langman & Dasgupta, 2012). A trial and error approach 
increases the risk of side effects, being over medicated, or the medication being 
ineffective to treat symptoms (Mrazek, 2010). This method of prescribing often delays 
the alleviation of symptoms due to an increase lag time in medication response taking 
weeks to months to find the right medication (Crettol, de Leon, Hiemke, & Eap, 2014).  
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 Currently, there are thirteen commercial pharmacogenetic tests available in the 
United States for psychotropic medications (Bousman & Hopwood, 2016).  GeneSight 
and Genecept are both pharmacogenetic tests that have demonstrated clinical usefulness 
in clinical trials in the United States (Bousman & Hopwood, 2016).  Pharmacogenetic 
testing requires genotyping, either buccal or blood, to obtain a DNA sample (Ng, 
Schweitzer, Norman, & Easteal, 2004). This single DNA test is one time test since a 
person’s genetic variations do not change during a person’s lifetime (Ng et al., 2004). 
Since 2004, pharmacogenetic testing has been used in academic and tertiary 
medical centers to guide treatment among patients with mental illness, however, such 
testing has not been used routinely in outpatient mental health practice (Hall-Flavin, 
Schneekloth, & Allen, 2010; Mrazek, 2010). More recently there has been a rapid 
expansion of pharmacogenetic testing in outpatient mental health settings (Brennan, 
2015). Unfortunately, many mental health providers are unfamiliar with such testing 
(Bousman & Hopwood, 2016).  
Previous Literature 
 Previous reviews of literature have focused on challenges for precision medicine 
in psychiatry, implications of pharmacogenetic testing in psychiatry, application of 
pharmacogenetics in mental health prescribing (Burke, Love, Jones, & Fife, 2016; Dalvie 
et al., 2016; Ng, Schweitzer, Norman, & Easteal, 2004). Additional literature reviews 
have focused on stakeholders’ views of pharmacogenetic testing and knowledge and 
attitudes of pharmacogenomics among healthcare professionals (Dodson, 2011; Patel, 
Ursan, Zueger, Cavallari, & Pickard, 2014). The latter two literature reviews do not have 
a specific emphasis on psychiatry but rather focus on healthcare professionals, general 
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public, patients, and payers (e.g., insurance companies and hospitals) (Dodson, 2011; 
Patel et al., 2014).  This review will focus on mental health clinicians and 
pharmacogenetic testing.  
Search Methods 
 A review of articles published from 2004 to 2017 was conducted on mental health 
clinicians’ knowledge, perceived attitudes, and implementation of pharmacogenetic 
testing. Pharmacogenetic testing was initially utilized to guide treatment among patients 
with mental illness in 2004, therefore the author chose to search the literature beginning 
in 2004 (Hall-Flavin, Schneekloth, & Allen, 2010; Mrazek, 2010).  A search was 
conducted using PubMed/Medline, CINAHL, PsycInfo, and Academic Search Complete 
databases. The following terms were utilized in a multi-search field: pharmacogenetics, 
personalized medicine, precision medicine, healthcare professionals, perceptions, 
attitudes, opinions, psychiatry, and mental health. Studies were included if the sample 
consisted of psychiatrists or other mental health clinicians (e.g., advanced practice nurses, 
physician assistants, and medical students in psychiatry).  
Search Results 
 The literature search yielded 97 relevant articles on mental health clinicians’ 
knowledge, perceived attitudes, and implementation of pharmacogenetic testing. Titles 
and abstracts were reviewed and articles that did not meet inclusion criteria were 
eliminated. Studies were excluded if one of the following occurred: sample included only 
non-mental health clinicians and interventions other than pharmacogenetic testing to 
guide treatment among patients with mental illness. There were eight relevant articles 
published from 2004 to 2017, see Table 1. The majority of the studies were quantitative 
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survey design while only one study was a mixed methods design and one study was a 
qualitative design. Most studies focused on psychiatrists or psychiatry residents. 
Table 1. Overview of Relevant Studies 
Author (year) 
 
Design Sample Knowledge Opinions & 
Perceptions 
Implementation  
 
1
1
 
Dunbar, Butler, 
Wheeler, Pulford, 
Miles, & Sheridan 
(2012) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Qualitative Total n=33 
Mental Health 
Clinicians  
Public Mental 
Health Services of 
three District 
Health Boards in 
New Zealand. 
n/a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perceived 
Usefulness 
Confirmed prior 
clinical decisions 
judgement 
regarding dosing. 
 
Explained why 
patients may have 
increased 
sensitivity to 
medications.  
 
Built a level of 
trust and rapport 
with the patients.  
 
Advantages:  
Determine the dose 
with the least 
amount of side 
effects.  
 
An indicator for 
starting dose of 
medications.  
 
Predict fewer side 
effects. 
 
Greater medication 
adherence. 
Ordering and 
Receiving of 
Pharmacognetic 
Test (AmpliChip 
CYP450)  
Advantages:   
Forms were 
straightforward and 
simple to complete. 
 
Disadvantages:  
Laboratory staff 
unfamiliar with test 
requiring additional 
blood samples 
from patient.  
 
Delay in receiving 
results (average 8 
days).  
 
Poor accessibility 
of test forms and 
lack of awareness 
of study end date. 
 
Reasons for not 
ordering test:  
Patient was 
discharged or did 
not return for 
service.  
Table 1. Continued 
Author (year) 
 
Design Sample  Knowledge Opinions & 
Perceptions 
Implementation  
 
 
 
1
2
 
Dunbar, Butler, 
Wheeler, Pulford, 
Miles, & Sheridan 
(2012) 
(continued) 
n/a Clinicians more 
confident in dosing 
decisions.  
 
Greater utility for 
patients who were 
“abnormal 
metabolizers” and 
at risk of side 
effects at low 
doses of 
medications.  
 
Potential 
Disadvantages:  
Clinicians focus on 
the blood test 
instead of the 
patient.  
 
Cost of test.  
 
Additional 
paperwork for 
provider. 
 
Delays in receiving 
results.   
 
Increased anxiety 
for patients due to 
process. 
Setting required 
immediate 
treatment and delay 
in results.  
 
Medication was 
stopped prior to 
obtaining test 
results.  
 
Patient was not 
experiencing side 
effects.  
 
Clinician unsure 
how to utilize the 
test results. 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Continued 
Author (year) 
 
Design Sample  Knowledge Opinions & 
Perceptions 
Implementation  
 
 
 
1
3
 
 
Finn, Wilcox, 
Korf, Blacker, 
Racette, Sklar, & 
Smoller (2005) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantitative Total n=352 
Psychiatrists  
 
Attending a 
continuing 
education medical 
education course, 
97% of 
participants from 
the United States 
or Canada. 
 
 
Less than 25% 
perceive 
themselves as 
competent to 
discuss genetic 
information 
regarding genetic 
testing with 
patients and 
families. 
 
87% routinely ask 
detailed family 
history of 
psychiatric illness 
during evaluation. 
 
40% of 
respondents stated 
that current 
medical literature 
was primary source 
of genetic 
information.  
 
27% from courses 
in medical training 
or clinical training  
 
22% from CME 
courses 
83% believe that it 
is their role to 
discuss genetic 
information with 
patients and 
families.  
 
 
n/a 
Table 1. Continued 
Author (year) 
 
Design Sample  Knowledge Opinions & 
Perceptions 
Implementation  
 
 
 
1
4
 
 
Finn, Wilcox, 
Korf, Blacker, 
Racette, Sklar, & 
Smoller (2005) 
(continued) 
 
7% from informal 
consultation with 
colleagues 
 
1% popular press 
or media 
 
3% other  
 
Respondents 
expressed further 
interest in genetic 
education:  
Written education 
materials (93%), 
CME courses 
(82%), 
Web/Internet 
Resources (81%), 
Multidisciplinary 
consultation with 
colleagues (77%). 
 
  
Hoop, Lapid, 
Paulson, & 
Roberts (2008) 
Quantitative Total n=45 
Psychiatrist 
chosen randomly 
from the American 
Medical 
Association 
Masterfile. 
No respondents 
referred patients 
for genetic 
consultation for 
psychiatric illness 
in the past year 
(n=43). 
78% of 
respondents 
believe psychiatrist 
should be the one 
to provide genetic 
counseling to 
patients. 
 
Table 1. Continued 
Author (year) 
 
Design Sample  Knowledge Opinions & 
Perceptions 
Implementation  
 
 
 
1
5
 
  
79% respondents 
did not order 
genetic test in past 
5 years (n=42).  
 
 
Genetics has an 
influence on 
overall mental 
health  
(mean, SD)  
(3.64, 0.48) 
Hoop, Lapid, 
Paulson, & 
Roberts (2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mixed Methods Total n=75 
Residents and 
Faculty  
In 3 Departments 
of Psychiatry 
Academic Centers 
in the United 
States—Mayo 
Clinic, University 
of Louisville, & 
Georgia Medical 
College  
 
Training 
Received  
(n=67) 
None: 5% 
Minimal: 56% 
Moderate: 21% 
Extensive: 5% 
 
Experience 
(n=59) (mean, SD)  
Ordered PGT in 
past 12 months  
(20.86, 48.5) 
 
14.7% did not 
order PGT in past 
12 months. 
 
64% ordered 
testing 1 or more 
times in past 12 
months. 
 
 
Perceived 
Usefulness 
 (n=64) (mean, 
SD) 
Medication 
tolerance (3.66, 
0.59) 
 
Treatment-
resistance 
Depression  
(3.60, 0.70) 
 
Chronic 
Schizophrenia 
(2.98, 0.86) 
 
Perceived Risks 
 (n=36) (mean, 
SD) 
Provide secondary 
information about 
susceptibility to 
disease or 
prognosis (2.89, 
Practices when 
Ordering PGT 
(x2, p-value) 
Inform patients test 
is being ordered 
(0.00, 1.000) 
 
Obtain patient’s 
verbal consent 
(0.22, .642) 
 
Inform about cost 
of test (1.57, .211) 
 
Test only patients 
if there is an 
immediate medical 
benefit (0.061, 
.804) 
 
Test only patients 
with decisional 
capacity (0.005, 
.942) 
 
Table 1. Continued 
Author (year) 
 
Design Sample  Knowledge Opinions & 
Perceptions 
Implementation  
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Hoop, Lapid, 
Paulson, & 
Roberts (2010) 
(continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.53) 
 
Cause a Patient 
Psychological 
Distress (2.85, 
0.58) 
 
 
 
Perceived Ethical 
Concerns 
(n=66) (mean, 
SD) 
 
Ensure 
confidentiality of 
Results (3.35, 
0.54) 
 
Competence in 
Interpretation of 
Results (3.30, 
0.58) 
 
Obtain Informed 
Consent Prior to 
test (3.29, 0.63) 
 
Pretest and Posttest 
counseling (3.20, 
0.66) 
 
Test patients who 
unlikely will have 
benefit but may 
gain information 
for future (.764, 
.382) 
 
Test only patients 
over 18 (0.09, 
.0764) 
 
Obtain patient’s 
written consent  
(6.61, <.05) 
 
Practices when 
Receiving PGT 
Results 
 
Meet with patients 
to answer questions 
and explain results 
(0.43, .514) 
 
File results in 
patients’ medical 
record (4.68, <.05) 
 
Tell patients that 
results may pertain 
to other family  
members (3.05, 
Table 1. Continued 
Author (year) 
 
Design Sample  Knowledge Opinions & 
Perceptions 
Implementation  
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Hoop, Lapid, 
Paulson, & 
Roberts (2010) 
(continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Provide test if 
benefits outweigh 
risks (3.05, 0.51) 
 
Provide test only to 
patients with 
decision making 
capacity (2.70, 
0.80) 
 
 
 
Perceived 
Professional 
Impact 
(mean) 
Psychiatric 
Patients would 
benefit from PGT 
(3.03) 
 
PGT would 
Dramatically 
change the practice 
of psychiatry 
(2.77) 
PGT too expensive 
for patients (2.60) 
(neither agreed or 
disagreed) 
 
Five Dominant 
.081) 
 
Communicate 
results to the 
patient’s primary 
doctor (0.001, 
.979) 
 
Tell patients that 
results  may 
provide secondary 
information (5.24, 
<.05) 
 
Create a separate 
file for test results 
kept apart from 
official medical 
record (4.56, <.05) 
 
 
 
 
 
Table 1. Continued 
Author (year) 
 
Design Sample  Knowledge Opinions & 
Perceptions 
Implementation  
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Hoop, Lapid, 
Paulson, & 
Roberts (2010) 
(continued) 
Themes from 
Qualitative 
Analysis:  
(n=17) 
Optimism about 
the  
potential of 
psycho-
pharmacogenetic 
testing. 
 
Dismissal of 
concerns about 
risks of testing.  
 
 
Identification of 
barriers to 
widespread clinical 
testing.  
 
General skepticism 
about current 
benefits of testing.  
 
Concerns that 
testing is being 
used 
inappropriately. 
 
 
Lanktree, Zai, Quantitative Total n=910 Exposure to 90% of  
Table 1. Continued 
Author (year) 
 
Design Sample  Knowledge Opinions & 
Perceptions 
Implementation  
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Vanderbeek, 
Giuffra, 
Smithson, Kipp, 
Dalseg, 
Speechley, & 
Kennedy (2014) 
Undergraduate 
Medicine and 
Science Students 
from the  
University of 
Waterloo (n=542), 
the University of 
Western Ontario 
(n=268), and the 
University of 
Toronto (n=100).  
 
genetic testing 
(86%) and mental 
illness (81%) in the 
classroom.  
 
 
 
respondents 
support using 
genetic 
information when 
determining 
medication 
treatment for 
patients with 
Schizophrenia. 
 
 
 
 
 
Mrazek, Drought, 
Koenig, et al. 
(2007) 
 
 
 
 
Quantitative 
 
 
 
 
Total n=41 
Psychiatrists 
76.47% 
Nurse 7.84 % 
Social Worker 
1.96% 
Psychologist 
1.96% 
Researcher 3.92% 
Other 7.84% 
 
Enrolled in a 5-
day course on 
psychiatric 
genomics at the 
Mayo Clinic. 
  
 
 
 
59% of 
respondents were 
willing to pay for 
2D6 and 2C19 
genotyping by the 
end of the course 
at the cost of $375 
 
95% would be 
willing to 
participate in a 
research project to 
receive the test at 
no cost.  
 
98% believed that 
 
Table 1. Continued 
Author (year) 
 
Design Sample  Knowledge Opinions & 
Perceptions 
Implementation  
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adults have the 
right to know their 
genotypes  
 
 
Thompson, 
Hamilton, & 
Hippman (2015) 
 
 
 
 
 
 
 
 
 
Thompson, 
Hamilton, & 
Hippman (2015) 
(continued) 
Quantitative Total n=113 
Psychiatrists and 
Psychiatry 
Residents  
 
From UCSF 
Langley Porter 
Psychiatric 
Institute and San 
Francisco Bay 
area community.  
 Perceptions:  
96% Believe that 
genetic 
information may 
help with decision 
making regarding 
medication in the 
treatment of 
psychiatric 
illnesses. 
 
 
97.3% Would use 
information if 
drug-drug 
interaction was 
indicated. 
 
85.1 % Believe 
that genetic testing 
will become 
standard of care in 
psychiatric 
treatment.  
 
72.6% Believe that 
genetic counseling 
 
Table 1. Continued 
Author (year) 
 
Design Sample  Knowledge Opinions & 
Perceptions 
Implementation  
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would be 
beneficial to 
discuss genetic test 
results. 
 
Walden, Brandl, 
Changasi, 
Sturgess, Soibel, 
Notaro, Cheema, 
Braganza, 
Marshe, Freeman, 
Tiwari, Kennedy, 
& Muller (2015) 
Quantitative Total n=168 
Psychiatrists 
(33.9%, n=57) 
Clinician 
Scientists (7.1%, 
n=12) 
General 
Practitioners 
(40.5%, n=68) 
Other specialties 
(18.5%,  n=31) 
From the Centre 
for Addiction and 
Mental Health in 
Toronto, Canada. 
 
 Perceptions:  
(mean, SD) 
Clinician scientists 
were more 
favorable of test 
than psychiatrist (p 
<0.05).   
 
80% of physicians 
believed 
pharmacogenetic 
testing would 
become standard 
of care in 
psychiatric 
treatment.  
Practices when 
ordering 
Pharmacogenetic 
Testing  
(TaqMan Assays): 
 
Obtain blood 
sample 
 
48 hour turn-
around time for 
genotyping 
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Mental Health Clinicians’ Knowledge of Pharmacogenetic Testing 
 Very little education is received by clinicians on pharmacogenetics in traditional 
medical programs (Gershon, Alliey-Rodriguez, & Grennan, 2014). Approximately 60% 
of physicians believe that only specialists have knowledge and understanding about 
pharmacogenetic testing (Tamaoiki, Gushima, & Tsutani, 2007). According to Collins 
(1999) most clinicians have received less than one hour of instruction on 
phamacogenetics. Researchers found that clinicians have made errors in translating 
pharmacogenetic testing results to patients due to lack of knowledge (Giardello et al., 
1997).  
 Research consistently shows clinicians typically report limited knowledge or 
understanding of pharmacogenetic testing. From a systematic review, Dodson (2011) 
found that five out of six articles confirmed that healthcare providers had limited 
knowledge on pharmacogenetic testing. However, only one of the six articles from 
Dodson’s (2011) systematic review looked at mental health clinicians’ knowledge on 
pharmacogenetic testing (e.g., psychiatry attending physicians and psychiatry residents) 
(Hoop, Lapid, Pualson, & Roberts, 2010).  
 Hoop et al., (2010) found that among a sample of 75 psychiatric faculty and 
residents, 61% had none to minimal training of pharmacogenetic testing while 26% had 
moderate to extensive training in pharmacogenetic testing. However, the study was 
conducted at three academic medical centers which were early adopters of 
pharmacogenetic testing. Therefore, the amount of training received may be larger than 
among outpatient psychiatrists (Hoop et al., 2010).  Researchers assessed psychiatric 
faculty and residents’ (n=67) competency level based on the following five items: belief 
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that it is a psychiatrist’s role to offer pharmacogenetic testing in appropriate clinical 
circumstances, order pharmacogenetic tests, identify clinical situations in which testing is 
indicated, inform patients of risks and benefits of testing, and make treatment 
recommendations based on results (Hoop et al., 2010). Participants were asked to rate 
their level of agreement on a scale of 1 to 5, 1 being strongly disagree and 5 being 
strongly agree. Participants with moderate to extensive training (mean = 3.38) rated 
themselves as more competent when compared to those with none to minimal training 
(mean 2.63) [F1,63 = 49.78, p<.001]. In addition, participants who have utilized 
pharmacogenetic testing in practice with in the last 12 months (mean = 2.96) rated 
themselves as more competent than those who had not ordered pharmacogenetic testing 
(mean = 2.36) [F1,56 = 16.33, p<.001] (Hoop et al., 2010).  
 Two additional studies focused on mental health clinicians’ knowledge of 
genetics and the likelihood of developing a mental illness (Finn et al., 2005; Hoop, 
Roberts, Hammond, & Cox, 2008). In a quantitative study, the majority of psychiatrists 
(60%) had not had recent genetic training within the past five years (Hoop et al., 2008). 
Respondents who had obtained genetic training in the in past 5 years had more 
experience with providing genetic testing (Hoop et al., 2008). However, 70% of 
psychiatrists felt competent to interpret genetic test results to patients regarding 
psychiatric illness. Many psychiatrists believed that their medical training prepared them 
for genetic counseling (Hoop et al., 2008). 
 In contrast, fewer than 25% of psychiatrists or psychiatrists in training (n=352) 
attending a continuing medical education course felt competent to discuss genetic 
information with patients and families (Finn et al., 2005). The majority of respondents 
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(40%) stated that their primary source of genetic information was obtained from the 
current medical literature. Additional respondents obtained educational resources on 
genetic information from medical or clinical training (27%), CME courses (22%), 
informal consultation with colleagues (7%), popular press or media (1%), or other (3%). 
Most respondents were interested in further genetic education via written education 
materials (93%), CME courses (82%), Web/Internet resources (81%), and 
multidisciplinary consultation with colleagues (77%) (Finn et al., 2005). Although these 
two studies focused on psychiatrists’ knowledge of genetics, this study did not assess 
knowledge of pharmacogenetics specifically.  
 A sample of undergraduate medicine and science students (n=910) from three 
different universities, University of Waterloo (n=542), University of Western Ontario (n-
268), and University of Toronto (n=100), completed questionnaires on pharmacogenetic 
testing for psychotropic medications (Lanktree et al., 2014). The majority of the 
respondents received information on genetic testing (86%) and mental illness (81%) in 
the classroom and believed that such testing should be utilized to determine which 
medication to prescribe (Lanktree et al., 2014). However, the knowledge of 
pharmacogenetic testing among the general public is less prevalent (Wilde, Meiser, 
Mitchell, & Schofield 2010). 
 To the author’s knowledge, no additional studies have assessed mental health 
clinicians’ knowledge of pharmacogenetic testing. Additional studies have focused on 
nursing students and other healthcare professionals (Dodson, 2014; Dodson  & LeWallen, 
2011; Haga, Burke, Ginsburg, Mills, & Agans, 2012; Kadafour et al., 2009; Kudzi, Addy, 
& Dzudzor, 2015; Selkirk, Weissman, Anderson, & Hulick, 2013; Stanek et al., 2012). 
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The majority of studies have focused on general practitioners, pharmacists, and nurses 
(Haga et al., 2012; Kadafour et al., 2009; Selkirk et al., 2013; Stanek et al., 2011).  
 Two studies focused on oncology nurses’ and undergraduate student nurses’ 
knowledge of pharmacogenetics (Dodson, 2014; Dodson & Lewallen, 2011). Among 
oncology nurses (n=368) 72 % perceived they had fair to poor knowledge of 
pharmacogenetics. Only three out of 368 oncology nurses were nurse practitioners 
(Dodson, 2014). Participants had greater knowledge of pharmacogenomics (mean = 2.45; 
SD = 1.4) when compared to genomic knowledge (mean = 2.62 SD = 1.44). Overall, 
nurses with previous experience with pharmacogenetic testing had greater knowledge 
(Dodson, 2014). Additional researchers found that among 275 undergraduate nursing 
students, 76% reported minimal to no knowledge of pharmacogenetics (Dodson & 
Lewallen, 2011).  
 Four additional studies focused on other healthcare professionals and their 
knowledge level of pharmacogenetic testing in clinical practice (Haga et al., 2012; 
Kadafour et al., 2009; Selkirk et al., 2013; Stanek et al., 2011). Researchers found 66% of 
healthcare professionals (n=448) had a general lack of knowledge of pharmacogenetics 
(Kadafour et al., 2009). The sample included pharmacists (n=268), nurses (n=102), 
physicians (n=52), physician assistants (n=5), and other healthcare professionals (n=3). 
Participants who had pharmacogenetic testing available at their workplace had more 
knowledge of pharmacogenetics. However, there was not a difference in knowledge 
between pharmacists and nurses (Kadafour et al., 2009).  
 Similarly, among a multidisciplinary group of physicians (n=249) (e.g., 
geneticists, internists, vascular surgeons, and oncologists), there is a general lack of 
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knowledge about genomics (73%) (Selkirk et al., 2013). Only 11.2% of physicians 
reported using pharmacogenetic testing in practice. A major barrier was the time required 
to stay abreast of knowledge of pharmacogenetics and latest advances in practice (70%) 
(Selkirk et al., 2013).  
 Additional researchers found that 52.4% of family medicine and internal medicine 
physicians (n=597) were not knowledgeable about genetic testing (Haga et al., 2012). 
Among respondents, 32% had never ordered genetic testing and 38.7% were not 
comfortable ordering such testing. Many respondents had heard of pharmacogenetic 
testing through journals (46.9%) or professional meetings (46.61%), but most 
respondents (79.6%) had never ordered pharmacogenetic testing. However, a large 
majority of physicians (64.5%) believed that pharmacogenetic testing will soon be 
valuable to predict adverse events and the effectiveness of medications (Haga et al., 
2012).  
 Researchers found that 97.6% of physicians (n=10,303) were favorable to 
genetics being influential to a patient’s drug response (Stanek et al., 2011). However, 
only approximately 10% felt competent about pharmacogenetic testing. Early adopters 
reported more knowledge about the clinical application of the test and had received 
pharmacogenetics training in medical school (26.3%) or post graduate training (44.2%) 
(Stanek et al., 2011).  
 Overall, mental health care clinicians and other healthcare professionals have a 
generalized lack of knowledge of genetics and pharmacogenetics. Additional assessments 
of mental health clinician’s knowledge are needed among outpatient and inpatient 
psychiatric providers. Early adopters seem to have more knowledge and understanding 
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about pharmacogenetics compared to those who have not utilized pharmacogenetic 
testing in practice. Many clinicians and healthcare professionals believe that 
pharmacogenetic testing will be valuable. There is a lack of education on 
pharmacogenetics in nursing and medical curricula. There is an urgency to understand the 
knowledge of pharmacogenetics testing among mental health clinicians as 
pharmacogenetic testing expands into outpatient clinics. 
Mental Health Clinicians’ Perceived Attitudes of Pharmacogenetic Testing 
 A mental health clinician’s perceived attitudes and opinions regarding 
pharmacogenetic testing is important in understanding the usefulness of such testing in 
practice. Six out of eight articles discussed mental health clinicians’ perceived attitudes 
regarding pharmacogenetic testing (Dunbar, Butler, Wheeler, Pulford, Miles, & Sheridan, 
2012; Hoop et al., 2010; Lanktree et al., 2014; Mrazek et al., 2007; Thompson et al., 
2015; Walden et al., 2015). Two additional articles discussed mental health clinicians’ 
perceptions of genetic testing in regards to the likelihood of psychiatric illness (Finn et 
al., 2005; Hoop et al., 2008).  
 Perceived usefulness. In several studies, researchers found that mental health 
clinicians perceived pharmacogenetic testing to be useful in clinical practice regarding 
medication selection and dosing (Dunbar et al., 2012; Hoop et al., 2010; Lanktree et al., 
2014; Thompson et al., 2015).  In a qualitative study of mental health clinicians (n=33) in 
New Zealand, mental health clinicians found the implementation of the AmpliChip 
CYP450 pharmacogenetic test to be useful in guiding treatment in patients with 
psychiatric illness (Dunbar et al., 2012). The AmpliChip CYP450 test was approved by 
the Federal Drug Administration in 2005. The test analyzes a patient’s DNA via a blood 
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sample to determine a patient’s phenotype for CYP2D6 and CYP2C19. The majority of 
patients (71%) were being prescribed antipsychotics for their psychiatric illness 
(psychotic disorder 55.2%, mood disorders 36.3%, other disorders 8.5%), while 
approximately 30% were prescribed risperidone versus other antipsychotics (Dunbar et 
al., 2012).  
 Researchers found that mental health clinicians reported several benefits of 
pharmacogenetic testing (Dunbar et al., 2012). First of all, clinicians found the testing to 
be useful in finding the right target dose and confirmed clinical decisions regarding 
medication selection and changes made previously, thus making clinicians more 
confident in their dosing selections. This provided reassurance in dosing changes (Dunbar 
et al., 2012). In a mixed methods study, Hoop et al. (2010) found that the majority of 
psychiatrist’s and residents in psychiatry (n=65) perceived pharmacogenetic testing most 
useful in medication tolerance (mean = 3.66, SD = 0.59) and treatment-resistance 
depression (mean = 3.60, SD = 0.70). Participant responses were on a scale from 1 (not 
useful) to 4 (extremely useful).  
 Similarly, other psychiatrists and residents in psychiatry (n=113, 96%) believe 
that pharmacogenetic testing may help in the decision-making process when treating 
patients with psychiatric illness (Thompson et al., 2015).  In addition, 90% of 
undergraduate medicine and science students (n=910) positively supported using genetic 
information in the treatment of Schizophrenia (Lanktree et al., 2014).  Mental health 
clinicians perceive that pharmacogenetic testing provides an explanation to patients 
regarding an increased sensitivity to medications (Dunbar et al., 2012). Thompson et al. 
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found 97.3% of psychiatrists and psychiatrist residents (n=113) perceived 
pharmacogenetic testing as being useful if a drug-drug interaction was indicated.   
 In addition, mental health clinicians found the test to be useful in developing a 
level of trust and rapport with patients (Dunbar et al., 2012). According to the clinicians, 
patients felt safer knowing that the clinician was aware of possible complications and 
side effects from medication. Clinicians predicted fewer side effects among medication 
and greater medication adherence among patients taking medications for psychiatric 
illness. Clinicians felt that this type of testing would be more beneficial for those 
classified as “abnormal metabolizers” who may be at a greater risk of side effects at low 
doses of medication (Dunbar, 2012).   
 Perceived professional impact. In a mixed methods study, psychiatrists and 
psychiatry residents believe that patients with mental illness would benefit from 
pharmacogenetic testing (mean = 3.03) (Hoop et al., 2010). Respondents used a scale of 1 
(strongly disagree) to 4 (strongly agree) to determine responses to questions concerning 
the professional impact of pharmacogenetic testing.  Psychiatrists and residents of 
psychiatry believe that pharmacogenetic testing would change the practice of psychiatry 
(mean = 2.77) and genetic testing would become the standard of care in the treatment of 
mental illness (n=113, 85.1%) (Hoop et al., 2010; Thompson et al., 2015). Additional 
psychiatrists (n=45) believe that genetics has a major influence on mental health (mean = 
3.64, SD = 0.48) (Hoop et al., 2008). Similarly, in another quantitative study, among 
psychiatrists (n=57), clinician scientists (n=12), general practitioners (n=68), other 
specialties (n=4), and unknown specialties (n=27), there was no difference among 
specialties regarding the belief that pharmacogenetic testing will become the standard of 
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care (p = 0.074) (Walden et al., 2015). In addition, 80% of physicians believe that 
pharmacogenetic testing will become the standard of care in psychiatry (Walden et al., 
2015). However, clinician scientists were more favorable (p<.05) regarding 
pharmacogenetic testing than psychiatrists (Walden et al., 2015).  
 Although 76.4% of respondents (n=113) who were engaged in pharmacogenetic 
testing were not familiar with genetic counseling, the majority of psychiatrists and 
psychiatry residents (72.6%) believe that genetic counseling would be helpful to discuss 
genetic results with patients (Thompson et al., 2015). In contrast, other researchers found 
that only 13% of psychiatrists (n=45) believe that genetic counselors are the most 
appropriate professional to provide genetic counseling to patients regarding the role of 
genetics in mental illness (Hoop et al., 2008). The majority of psychiatrists (78%) believe 
that the psychiatrist should be the person to provide genetic counseling to patients; 
however, 80% of psychiatrists had not ordered any genetic test within the last 5 years 
(Hoop et al., 2008). In another quantitative study, researchers found similar results where 
83% of psychiatrists (n=352) believe that it is their role to discuss genetic information 
with patients and families (Finn et al., 2005). Approximately 23% of psychiatrists (n=45) 
believe that telling patients there is a genetic component to their illness will reduce 
anxiety about having a psychiatric disorder (Hoop et al., 2008).  
 Although the majority of psychiatrists believe that pharmacogenetics will become 
the standard of care, there is a consistent lack of knowledge among psychiatrists 
regarding such testing. In addition, clinicians who are early adopters or in academic or 
research settings have more training and knowledge of pharmacogenetic testing. 
Therefore, the previous study may not represent the average mental health clinician in 
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outpatient clinics. There are mixed results regarding whether genetic counseling should 
be conducted by psychiatrists or genetic counselors. Additional studies are needed to 
evaluate the competency of mental health clinicians regarding educating patients about 
pharmacogenetic testing results. 
 Perceived barriers. Although many benefits exist, mental health clinicians 
(n=33) identified several potential barriers to the CYP450 AmpliChip pharmacogenetic 
test in clinical practice (Dunbar et al., 2012). First of all, mental health clinicians were 
concerned that providers would focus more on the DNA blood test than using clinical 
judgement regarding the patient (Dunbar et al., 2012). In addition, other psychiatrists and 
residents of psychiatry (n=36) agreed (mean = 2.89, SD = 0.53) that providing secondary 
genetic information about susceptibility to a disease or prognosis is a possible risk (Hoop 
et al., 2010). Responses were on a scale from 1 (strongly disagree) to 4 (strongly agree). 
Other risks included a negative effect on patients’ insurability (mean = 2.74, SD = 0.61) 
and causing patients psychological distress (mean = 2.85, SD = 0.58) (Hoop et al., 2010).  
 Several researchers found that mental health clinicians were concerned about the 
cost of the test (Dunbar et al., 2012; Hoop et al., 2010; Mrazek et al., 2007). In one study, 
clinicians were not provided with any information regarding the cost of the CYP450 
AmpliChip pharmacogenetic test; however, the financial impact on patients was a 
concern and how it would impact clinical services to this vulnerable population (Dunbar 
et al., 2012). In another mixed methods study, researchers found that early adopter 
psychiatrists and residents (n=75) did not agree or disagree (mean =2.60) that 
pharmacogenetic testing would be too expensive for patients (Hoop et al., 2010). In 
another quantitative study, the majority of psychiatrists (69%) were not knowledgeable of 
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genetic laboratories in their local geographic area and 82% of respondents were not 
aware of insurance coverage for such testing (Hoop et al., 2008). However, early (48.7%) 
and future adopters (44.9%) were more likely to believe that insurance would cover 
pharmacogenetic testing compared to those who had not adopted testing in their practice 
(29.6%) (Stanek et al., 2011). Among psychiatrists (76.47%) and other mental health 
professionals (n=41) enrolled in a week-long course in psychiatric genomics, 59% of 
respondents were willing to pay $375 for CYP2D6 and CYP2C19 genotyping by the end 
of the course and 95% of respondents were willing to participate in a research project to 
receive the test at no cost (Mrazek et al., 2007). According to Bousman and Hopwood 
(2016), uninsured patients can be charged up to $3,800.00 with an optional payment plan 
for pharmacogenetic testing. However, some third-party payers may have agreements 
with the pharmacogenetic company to offer the test at a different cost (Bousman & 
Hopwood, 2016). 
 Another major concern among psychiatrists and psychiatric residents (n=66) 
regarding pharmacogenetic testing was perceived ethical concerns (Hoop et al., 2010). 
Respondents were given statements regarding ethically relevant aspects of such testing 
which were scaled from 1 (strongly disagree) to 4 (strongly agree). Respondents believed 
that psychiatrists must ensure confidentiality of results (mean = 3.35, SD = 0.54), 
demonstrate competence in interpretation of results (mean = 3.30, SD = 0.58), obtain an 
informed consent prior to testing (mean = 3.29, SD = 0.63), provide pretest and posttest 
counseling (mean = 3.20, SD = 0.66), provide tests only if benefits outweigh risks (mean 
= 3.05, SD = 0.51), and provide tests only to those who have decision making capacity 
(mean = 2.70, SD = 0.80) (Hoop et al., 2010).  
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 In addition, clinicians were concerned about time restraints to order and perform 
the test in the clinical setting (Dunbar et al., 2012). For example, several respondents 
were concerned about practical issues such as having the test order forms readily 
available, delays in receiving test results, additional blood tests for patients, and 
unwarranted stress on the patient during this process leading to increased patient anxiety. 
Test results were received in eight days on average, however, some results were not 
available until forty-two days which became problematic for patients receiving treatment 
in an inpatient setting (Dunbar et al., 2012). 
 Despite perceived barriers, psychiatrists and psychiatry residents (n=17) in a 
mixed methods study are optimistic about pharmacogenetic testing and believe that such 
testing will not impact insurance or employment status more than the current diagnosis 
and treatment (Hoop et al., 2010). However, some believe that insurance and informed 
consent are the greatest barriers along with limited training on ethical issues. Although 
psychiatrists and psychiatry residents found pharmacogenetic testing useful for 
prescribing antidepressants and antipsychotics, respondents desire additional peer-
reviewed published evidence to support pharmacogenetic testing. Some respondents 
believe that there is some general skepticism about the benefits of pharmacogenetic 
testing. Lastly, respondents were concerned that clinicians are using pharmacogenetic 
testing inappropriately and often presenting pharmacogenetics to patients as “the answer” 
rather than providing pretest and posttest counseling about the test and results (Hoop et 
al., 2010). 
 Overall, there are several authentic concerns about pharmacogenetic testing in 
psychiatry. The majority of mental health clinicians believe that pharmacogenetic testing 
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is useful but have some concerns regarding inappropriate use of the test, cost of the test, 
ethical concerns, potential impact on employment or insurance, and limited training on 
pharmacogenetic testing. Additional studies are needed to further assess these barriers in 
outpatient mental health clinics.  
Implementation of Pharmacogenetic Testing in Mental Health 
 Pharmacogenetic testing is being used to guide treatment in a variety of illnesses 
including: cardiovascular disease, cancer, diabetes, autoimmune disease, infectious 
disease, pain management, and mental health (Hess et al., 2015). Presently, there are 
thirteen pharmacogenetic tests available in the United States in psychiatry (Bousman & 
Hopwood, 2016). Researchers have found pharmacogenetic testing to demonstrate 
clinical utility as a guide to medication selection in two open-label cohort studies and one 
randomized, double-blind controlled trial (Hall-Flavin et al., 2012; Hall-Flavin et al., 
2013; Winner et al., 2013). In all three studies, participants who received 
pharmacogenetic testing experienced a greater improvement in depressive symptoms 
when compared to the unguided group (Hall-Flavin et al., 2012; Hall-Flavin et al., 2013; 
Winner, Carhart, Altar, Allen, & Dechairo, 2013). Future research is needed to determine 
when to implement pharmacogenetic testing, how to interpret results, and how to 
implement findings in clinical practice (e.g., medication planning and monitoring and 
patient and family education).  
 There is a lack of clear clinical guidelines on how to implement these tests into 
practice (Relling & Evans, 2015). In 2006, clinical guidelines for CYP2D6 and 
CYP2C19 were published for clinical dose recommendations for antipsychotics and 
antidepressants, selection of a laboratory, and interpretation of tests (de Leon, Armstrong, 
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& Cozza, 2006). In 2009, the Clinical Pharmacogenetics Implementation Consortium was 
formed to establish evidence-based guidelines for clinicians, but does not specify who 
should receive these tests (Relling & Klein, 2011). There is a need to understand how 
pharmacogenetic testing should be implemented in clinical decision-making and 
determine what type of patient would benefit the most from such testing (e.g., 
children/adolescent, adults, and geriatrics; patients with multiple medication failures; 
newly diagnosed patients; patients experiencing side effects from medications, etc.). 
According to Relling and Evans (2015), many predict each individual will have their 
entire genome sequenced early in life.  
 Two studies focused on the implementation of pharmacogenetic testing in 
psychiatry (Dunbar et al., 2012; Hoop et al., 2010). In a qualitative study, mental health 
clinicians (n=33) implemented the AmpliChip CYP 450 test to guide treatment of 
patients mostly with a diagnosis of a psychotic disorder or mood disorder (Dunbar et al., 
2012). Clinicians completed a specific laboratory request form which was given to 
patients to take to a diagnostic clinic for a blood sample. The blood sample was sent to a 
central testing center and test results were posted electronically and paper copy sent to the 
clinicians. In this study, the laboratory was not familiar with the test resulting in extra 
blood samples taken from patients. In addition, there was a delay in clinicians receiving 
results. The average number of days from blood sample to dissemination was 8 days on 
average; however, some took 42 days to obtain results (Dunbar et al., 2012). A delay in 
results was a major barrier to clinicians ordering the test. In contrast, clinicians and 
scientists (n=168) who utilized another pharmacogenetic test, TaqMan Assays, obtained 
blood samples and received genotyping results within 48 hours (Walden et al., 2015).  
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 In a mixed methods study, psychiatrists and psychiatry residents (n=75) discussed 
practices when ordering pharmacogenetic testing and receiving results (Hoop et al., 
2010). The majority of psychiatrists and residents routinely informed patients of the test 
being ordered (X2 = 0.00, P = 1.000), obtained patient’s verbal consent (X2 = 0.22, P = 
0.642), informed patients about the cost of the test (X2 = 1.57, P = 0.211), tested only 
patients with an immediate medical benefit (X2 = 0.061, P = 0.804), and tested only those 
with a decisional capacity (X2 = 0.005, P = 0.942).  Standard practices among the 
majority of psychiatrists and residents included meeting with the patients to discuss 
results and answer questions (X2 = 0.43, P = 0.514), filing results in patients’ records (X2 
= 4.68, P <.05), and communicating results to primary care provider (X2 = 0.001, P = 
.979). However, in another study, several clinicians did not find it necessary to order 
pharmacogenetic testing if a patient was not experiencing side effects from medications 
or if medication was stopped prior to results (Dunbar et al., 2012). In addition, clinicians 
reported they were unsure how to utilize the test results (Dunbar et al., 2012). 
 Overall, there is a consistent lack of guidance on how clinicians should use the 
information obtained from pharmacogenetic testing (Drozda, Muller, & Bishop, 2014). 
Other researchers have suggested implementing a multidisciplinary team to disseminate 
pharmacogenetic test results in a community health system (Dunnenburger et al., 2016). 
For example, the team would consist of a medical geneticist, a pharmacist, a nurse 
practitioner, and genetic counselors. The team would provide the following components: 
a billable service provider; documentation of family histories and medications; personnel 
to interpret test results discuss risks benefits, and limitations of testing; and a process for 
reporting results (Dunnenberger et al., 2016). Research suggests that the utilization of 
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pharmacogenetic testing in clinical practice will require structured algorithms and 
implementation of clinical decision support aids to guide medication prescribing (Overby 
et al., 2014; Relling & Evans, 2015). Relling and Evans (2015) propose that there is a 
growing body of evidence of pharmacogenetics expanding in the future and will become 
a significant component of evidence-based precision medicine.  
  Clinicians must know when to use pharmacogenetic testing, who should receive 
testing, and how to interpret results (Robertson, Brody, Buchanan, Kahn & McPherson, 
2002). Currently, no guidelines exist for who should receive pharmacogenetic testing and 
how to translate results into practice (Abul-Husn, Owusu Obeng, Sanderson, Gottesman, 
& Scott, 2014). The implementation of pharmacogenetic testing will require collaboration 
between the clinician and laboratories which can be time consuming for busy clinicians 
(Burke, et al., 2016). Although these challenges exist, pharmacogenetic testing is a 
promising test that can assist clinicians in making informed clinical decision regarding 
medication planning and monitoring (Burke, et al., 2016; Davies, Conley, & Puskar, 
2010).  
Roger’s Diffusion of Innovation Model 
 Rogers’ Diffusion of Innovation (DOI) theory (Rogers, 2003) guides the study.  
DOI theory suggests innovation adoption involves five stages. In the knowledge stage 
(influenced by variables such as prior experience, perceived need for innovation, attitude 
toward change, personality variables, demographic variables, communication behavior, 
work environment, and others), an individual begins to seek information about the 
innovation to learn how and why it works. In the persuasion stage, an individual forms 
opinions and beliefs about the innovation is persuaded to accept it. In the decision stage, 
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an individual chooses to adopt or reject the innovation, followed by an implementation 
stage. The confirmation stage occurs after a decision has been made and the individual 
seeks support for his or her decision (Rogers, 2003).  
 This study will focus on the first four stages of innovation as described in DOI 
theory:  knowledge of pharmacogenetic testing (knowledge), beliefs and opinions about 
pharmacogenetic testing (persuasion), factors that influence decisions to utilize 
pharmacogenetic testing (decision), and how the test is being implemented in current 
outpatient mental health clinics (implementation) (See Figure 1). Using DOI theory will 
illuminate the process of the adoption and diffusion of pharmacogenetic testing in mental 
health practice. This study will be used to identify elements of the theory that may 
influence adoption and diffusion rather than to explain why pharmacogenetics is being 
used in outpatient mental health clinics. 
 Although recent research describes the knowledge, perceptions, and opinions of  
psychiatrists and other healthcare professionals on pharmacogenetic testing, few studies 
explore knowledge and perceptions of those who are utilizing the test in clinical practice. 
The majority of mental health clinicians believe that pharmacogenetic testing will 
become the standard of care in psychiatry. However, throughout the literature there is a 
consistent lack of knowledge among healthcare providers regarding pharmacogenetic 
testing even though clinicians are ordering these tests. Despite the expansion of 
pharmacogenetic testing in psychiatry, there is a lack of clear guidelines for translating 
pharmacogenetic testing into clinical practice. In addition, no studies found examined the 
knowledge, perceptions and opinions of mental health advanced practice nurses and 
physician assistants who are utilizing pharmacogenetic testing in practice to guide 
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treatment decisions. Further research is needed to evaluate the knowledge level of 
pharmacogenetics among mental health clinicians and how these clinicians are 
implementing pharmacogenetics into clinical decision making and workflow.  
 
 
Figure 1. Rogers’ Diffusion of Innovation Theory 
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Chapter III 
Design and Methods 
Purpose 
 The purpose of this qualitative descriptive study is to evaluate mental health 
clinicians’ perceived knowledge regarding pharmacogenetic testing, their attitude, 
receptivity towards, and confidence in pharmacogenetic testing, and how 
pharmacogenetic testing is being implemented to support precision medicine in outpatient 
clinics.   
Specific Aims 
1.  To describe clinicians’ perspectives on using pharmacogenetic testing in 
outpatient mental health clinics where such testing is routinely used, including 
their perceived knowledge, attitudes, and confidence in pharmacogenetic testing. 
2.  To describe clinicians’ practices of using pharmacogenetic testing in outpatient 
mental health clinics including shared decision-making, determining who is 
tested, medication planning and monitoring, and patient and family education.  
 This study provides a solid foundation for future research to support precision 
medicine around pharmacogenetic testing and medications (e.g., examining patient 
perspectives and testing influence on outcomes such as decision conflict, medication 
adherence, and illness trajectories) and intervention development (e.g., patient decision 
aids) among patients with mental illness (Substance Abuse and Mental Health Services 
Administration, 2010). 
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Methodology 
Research Design 
 Little is known about mental health clinicians’ knowledge and perceptions of 
pharmacogenetic testing or how such testing is being implemented in outpatient mental 
health clinics. Therefore, we conducted a qualitative descriptive study with mental health 
clinicians, a research approach which is appropriate for exploratory, flexible, and holistic 
research questions (Mason, 2002; Polit & Beck, 2016).  
Sample 
 Purposeful, maximum variation sampling included prescribing mental health 
clinicians in outpatient settings using pharmacogenetic testing in their current practice. 
Mental health clinicians including physicians, advanced practice nurses (i.e., clinical 
nurse specialists and nurse practitioners in psychiatry), and physician assistants who are 
actively utilizing pharmacogenetic testing and prescribing psychotropic medications in 
outpatient mental health clinics were eligible for inclusion in the study. Each clinician’s 
perspective is necessary to understand how pharmacogenetic testing is being 
implemented in clinical practice. Exclusion criteria included clinicians who are not 
currently working in mental health outpatient clinics and are not utilizing 
pharmacogenetic testing in their current practice.  
Sample Size and Configuration 
 The study will be conducted in mental health outpatient clinics located in upstate 
South Carolina, a region with approximately 80 mental health clinicians. Data collection 
will continue until data saturation is reached (Mason, 2002). The sample size was 28 
participants. The P.I. interviewed approximately five to ten participants per month. In 
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order to reach data saturation recruitment was expanded to target mental health clinicians 
in other regions of South Carolina and nationally. In addition, a snowballing sampling 
technique was used by asking early informants to refer potential study participants.   
 The P.I. outreached to mental health clinics by flyer and telephone and email 
follow-ups, and used her network as a mental health provider. In addition, the P.I. utilized 
national organizations such as listservs to recruit potential participants. Interested 
participants contacted the P.I. by phone or email. Following a screening and verbal 
informed consent process, the P.I. scheduled a telephone or in-person interview with the 
participant per their preference. The interview was scheduled at a convenient and private 
time and place of the participant’s choosing. Upon completion of the interview, the 
participant received a $25 gift card for participation in the study. 
Procedure 
 At the scheduled in-depth interview, the P.I. reconfirmed that all inclusion criteria 
were met and provided an opportunity to answer any questions that the participant may 
have regarding the study before the recording process begins. In addition, the P.I. 
discussed the participation of the study in detail and obtain both written and verbal 
consent before starting the in-depth interview. Following an informed consent process, 
the P.I. proceeded with an in-depth audio-recorded interview that lasted between 30 
minutes and 60 minutes. Participants were re-contacted to clarify or confirm data, as 
determined during data analysis.  
Instruments 
 Demographic form. Included variables important to clinician decision-making 
identified in literature review and according to DOI theory, e.g., age, gender, professional 
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title, years of experience as a mental health clinician, and years of experience using 
pharmacogenetic testing (see Appendix A) (Hoop et al., 2010; Walden et al., 2015).  
 Semi-structured interview guide. Included open-ended questions and follow-up 
probes, based on literature review and the P.I.’s clinical experience (see Appendix B). 
Participants were encouraged to speak freely, but a semi-structured interview ensured that 
certain topics are covered during the interview (Polit & Beck, 2016). Questions were 
framed around knowledge, persuasion, decision, and implementation stages of the DOI 
theory: e.g., knowledge, beliefs and opinions about pharmacogenetic testing, decision-
making factors, and implementation strategies. The P.I. piloted the interview guide with 
two mental health clinicians and revised the interview guide with dissertation committee 
input. Additionally, questions were iteratively revised during data collection in response 
to developing themes and to saturate data categories. 
Data Collection 
 Data collection was through semi-structured interviews conducted by the P.I. 
only. A semi-structured interview ensured that certain topics were covered during the 
interview (Polit & Beck, 2016). The P.I. encouraged the participant to talk freely about 
the topics on the interview guide. At the conclusion of the interview, the P.I. discussed 
with the participant that they may be contacted again if additional questions arise or if 
further clarification is needed once the P.I. has reflected on the information.  
Data Management 
 In addition to audio recording the interview, the P.I. dictated notes immediately 
after the interview, to prevent information loss if there is an improper recording of the 
initial interview and ensure reliability of data (Polit & Beck, 2016). The interview and 
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notes were fully transcribed verbatim by a professional transcriptionist.  Audio recordings 
were uploaded to a secure box drop on a secure computer. Transcripts were identified by 
a randomly assigned code to ensure participant privacy. The P.I. compared all transcripts 
to audio recordings to ensure accuracy. Transcripts were loaded into QSR NVivo 11, a 
qualitative data software package, for analysis. All hard copies, secure files, and written 
notes were stored in a secure, locked file cabinet and will be kept for seven years after the 
completion of the research project and manuscripts are published. Only the P.I. has 
access to the locked files.  
Data Analysis 
 Data analysis and interpretation were based on qualitative descriptive analysis 
methods. A qualitative descriptive analysis approach was used to develop codes as 
outlined by Miles and Huberman (1994). Coding began as soon as the first interview has 
been transcribed and reviewed for accuracy. Each transcript was read and coded for 
clinicians’ perspectives of pharmacogenetic testing (knowledge, attitudes, and 
confidence) and how it is being implemented in outpatient mental health clinics. After 
initial coding, the codes were grouped into categories. A constant comparison of the data 
was used with subsequent interviews to allow for an analysis of both within the 
individual case and across cases. Analysis prioritized identification of categories and 
themes related to the specific aims of the study. 
Validity 
 The P.I. utilized several methods to ensure credibility and reliability of findings. 
Respondent validation was used to verify credibility of interpretations by confirming 
categories and themes with participants (Mason, 2002). The P.I. recorded field notes and 
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a summary of the interview after each interview to prevent loss of information if there is 
an improper recording of the initial interview (Polit & Beck, 2016). In addition, the P.I. 
kept records to justify steps of interpretation (Mason, 2002). Lastly, the P.I. worked 
closely with her advisor, an expert in qualitative descriptive research, who audited 
activities of the P.I. to enhance dependability and trustworthiness of the study. 
Limitations 
 Limitations of the study included sampling and transferability. Sampling in 
qualitative research can be challenging since the access population may not represent the 
full target population and sample sizes may be significantly smaller (Polit & Beck, 2016). 
In this study, the P.I. recruited from the upstate region of South Carolina; however, since 
theory-saturation point was not achieved then the recruitment was expanded to other 
regions of South Carolina and the United States. Although the population does not 
represent a large geographic area, this study does have credibility (Polit & Beck, 2016) 
and represent clinicians who are utilizing pharmacogenetic testing in current outpatient 
mental health practices within this specified region. In addition, results are reported in 
terms of who responded (i.e., psychiatrist, advanced practice nurse, and physician 
assistants) to reduce sampling bias. This information is valuable to identify general 
patterns in clinicians’ experiences with pharmacogenetic testing in outpatient mental 
health clinics. 
Protection of Human Subjects 
 Approval was obtained for this study from the University of Missouri Health 
Sciences IRB. Purposeful, maximum variation sampling was used to recruit up to 28 
participants who are prescribing mental health clinicians in outpatient mental health 
clinics. These clinicians have been using pharmacogenetic testing in their clinic. 
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Participants were not excluded based on age, gender, or race. Subjects did not include 
children, prisoners, or other vulnerable populations because the focus is on the experience 
of clinicians. There is the potential for pregnancy among participants; however, these 
women were not be excluded. Data collection techniques in this study were little or no 
risk to these subjects. 
 Inclusion criteria are: prescribing mental health clinicians (psychiatrists, physician 
assistants, advanced practice nurses (i.e., nurse practitioners and clinical nurse 
specialists), and clinical psychologists) who were working in outpatient clinics and are 
currently using pharmacogenetic testing in their clinical practice. The only exclusion 
criteria were mental health clinicians who were not prescribing medications and did not 
currently using pharmacogenetic testing in their practice. 
  Data collected from participants were recorded via digital audiotape during 30 to 
60 minute in-depth interviews. Two audio recorders were used and one audio recording 
was deleted once it is verified that one audio is available. Observations of the participant 
including the physical setting and participant characteristics were documented 
immediately following the interview. Transcriptionists were provided with any required 
IRB training and the P.I. provided instructions to ensure anonymity, privacy, and 
confidentiality of participants and others that may be described by the participant. Within 
one week, the audio recordings were transcribed using Express Scribe Transcription 
Software and Microsoft Word software within the secure box drop. Transcripts were 
identified by a randomly assigned code to ensure privacy of the participant. The P.I. 
reviewed all transcripts by listening to the recording and reading along with the text to 
ensure accuracy. Transcripts were loaded into QSR NVivo 10, a qualitative data software 
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package, for analysis. All hard copies, secure files, and written notes by the P.I. were 
stored in a secure, locked file cabinet and will be kept seven years after completion of the 
research project and manuscripts are published. Only the P.I. has access to the locked 
files.  
 Risks. There are no physical, financial, legal or other risks to participants. 
Interviews focused on knowledge, perceptions, and implementation of pharmacogenetic 
testing and were not be emotionally upsetting to participants. The IRB at the University 
of Missouri reviewed and approved all study procedures. The P.I. explained the purpose 
of the study and obtain informed consent. Transcriptionists received any required IRB 
training. All data were de-identified and all study documents were locked in a secure file 
cabinet and kept seven years after completion of the research project and manuscripts are 
published.  
 Benefits. Benefits to participants were limited but participants have a better 
understanding of their use of pharmacogenetic testing through reflection during 
interviews. Benefits to mental health clinicians included a greater understanding of how 
pharmacogenetic testing is being utilized in mental health outpatient clinics, as well as 
any educational needs for clinicians who are using these tests. This in turn benefited 
clinicians to determine future clinical implications and integration of pharmacogenetic 
testing in routine clinical practice.  
 Participants may not personally benefit from interviews, but will contribute to 
better understanding of how pharmacogenetic testing is used in mental health outpatient 
clinics and clinicians’ and patients’ educational needs. Understanding how 
pharmacogenetic testing is being implemented can identify needed practice/policy 
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changes, improve patient outcomes, and provide a foundation for future intervention 
development. 
Conclusion 
 Although many mental health clinicians believe that pharmacogenetic testing will 
become the standard of care, the previous literature consistently shows a lack of 
knowledge of pharmacogenetic testing. However, clinicians are ordering tests but are 
unable to translate results into clinical practice. No guidelines exist on how to implement 
pharmacogenetic testing in clinical decision making. Further studies are necessary to 
further evaluate the knowledge level of mental health clinicians utilizing 
pharmacogenetic testing and the development of evidence based guidelines for 
implementation of pharmacogenetic testing in clinical practice. The majority of studies 
have been conducted in academic or research settings rather than outpatient settings. This 
study provides a foundation for future studies to develop future education material and 
decision-making aids for mental health clinicians using pharmacogenetic testing in 
outpatient clinics.  
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Chapter IV 
FINDINGS 
 
Many mental health clinicians in this sample found pharmacogenetic testing to be 
helpful in their current practice. For many of these clinicians, the integration of 
Pharmacogenetic testing reduced trial and error in prescribing medications and improved 
patient outcomes. Clinicians in this sample found the test to be scientific and an 
additional tool for dosing medications. Additionally, clinicians found the test results to be 
consistent with patient reports regarding tolerability and efficacy of medications used in 
the past. This chapter focuses on the demographics of the sample, experiences of this 
sample of mental health clinicians as they use pharmacogenetic testing to guide their 
clinical decision making.  
Demographics 
Study participants included Nurse Practitioners (n=16), Nurse 
Practitioner/Clinical Nurse Specialist (n=3), Physician Assistants (n=2), and Medical 
Doctors Board Certified in Psychiatry (n=7) (Table 2).  The majority of clinicians were 
females (n=20) and were between forty and sixty-nine years of age (n=24). Years of 
experience as a mental health clinician ranged from one year to thirty-five years. The 
majority of clinicians had one to five years of experience (n=21) using pharmacogenetic 
testing in clinical practice (Table 3). Most clinicians in this sample seen a range of 101 to 
399 patients per month (n=21) and ordered pharmacogenetic testing for one to five 
percent of patients (n=15). 
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Table 2. Demographics 
Professional Title 
 
 
NP/CNS (n=3) 
NP          (n=16) 
PA          (n=2) 
MD         (n=7) 
Age 
 
 
20-29 (n=1) 
30-39 (n=1) 
40-49 (n=8) 
50-59 (n=8) 
60-69 (n=8) 
70-79 (n=2) 
Gender 
 
 
Male  
(n=8) 
Female (n=20) 
Yrs. of Exp. 
Mental 
Health 
Clinician 
 
1-3 (n=6) 
4-6 (n=5) 
7-10 (n=3) 
11-14 (n=1) 
15-18 (n=5) 
19-21 (n=2) 
22-25 (n=1) 
26-30 (n=2) 
31-35 (n=3) 
 
*NP (Nurse Practitioner), CNS (Clinical Nurse Specialist), PA (Physician Assistant), MD (Medical 
Doctor) 
 
Table 3. Description of Utilization of Pharmacogenetic Testing 
Yrs./Months 
Using 
Pharmacogenetic 
Testing 
 
 
0-6 months (n=3) 
7-12 months (n=3) 
1-2 years (n=11) 
3-5 years (n=10) 
6-8 years (n=0) 
9-12 years (n=1) 
Testing Company 
 
 
 
 
GeneSight   (n=26) 
Genomind   (n=5) 
Millennium  (n=2) 
IDgenetix     (n=1) 
Ventari         (n=1) 
Natural  
Molecular    (n=1) 
Percentage of 
Patients 
Receiving 
Pharmacogen
etic Testing 
(%) 
 
<1      (n=2) 
1-5     (n=15) 
6-10   (n=4) 
11-15 (n=0) 
16-20 (n=0) 
21-29 (n=0) 
30-39 (n=3) 
40-49 (n=1) 
50-59 (n=2) 
>60     (n=1) 
Average 
Number of 
Patients Seen 
per Month  
 
≤100      (n=4) 
101-199 (n=8) 
200-299 (n=6) 
300-399 (n=7) 
400-499 (n=1) 
≥500       (n=2) 
    
 
A Tool for Prescribing 
 For many mental health clinicians in this sample, pharmacogenetic testing is an 
additional tool being utilized to assist with medication selection and dosing for patients 
with mental illness. One clinician stated, “I think it’s just given us another tool, another 
avenue, a little bit more information in choosing a medication.” Some clinicians believe 
that it is beneficial to utilize this tool with every patient while others found that it is not 
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feasible to do the test unless it is warranted medically. Clinicians perceive that this test 
provides them with more direction in prescribing medications. For example, the test 
guides the clinician to be more conservative or more aggressive with dosing. Some 
clinicians reported that usual practice is to “start low and go slow” with medications but 
the pharmacogenetic test helps to determine if you need to start even at a lower dose due 
to metabolism issues.  
How the Test Works 
 The test is performed by conducting a buccal swab or saliva specimen to obtain a 
DNA sample. Most clinicians in this sample have the patient or nurse collect the sample.  
The clinician sends the DNA sample to the lab and results are sent to the clinician. The 
timeframe to receive results varied from 48 hours to three weeks.  
 The pharmacogenetic test provides information on how certain medications are 
metabolized including antipsychotics, antidepressants, anxiolytics, hypnotics, ADHD 
medications, mood stabilizers, pain medications and folic acid conversion. However, 
some of the tests also provided information beyond psychiatry. One clinician reported it 
is important for others to understand that “the test is not specific to psychiatry but 
specific to an individual’s DNA”. Clinicians agreed that the test looks at different genetic 
markers which may indicate if a patient will metabolize a medication more quickly or 
more slowly and may be more likely to have side effects from medication based on 
genetic markers DNA.  
Choosing a Testing Company 
 Clinicians used a variety of pharmacogenetic tests in their practice including: 
Genesight, Genomind, Millennium, IDgenetix, Ventari, and Natural Molecular. The 
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majority of clinicians utilized Genesight or Genomind. Clinicians recommended doing 
research on the various pharmacogenetic testing companies before choosing a company. 
The majority of clinicians believed that it is important to choose a pharmacogenetic test 
with a good reputation and that is evidence based.  Most clinician’s recommended talking 
to other providers who are using pharmacogenetic testing in practice to learn about their 
experiences when choosing a testing company. 
Initial Exposure to Pharmacogenetic Testing 
 The majority of clinicians in this sample learned about pharmacogenetic testing 
from peers that had been using the test in clinical practice.  Additional clinicians learned 
about pharmacogenetic testing through educational settings including internships and 
curriculum in DNP, PhD, and Master’s programs. Some read about pharmacogenetic 
testing in the literature but did not learn specifics about the test until the pharmacogenetic 
testing company representative came by their clinic. Many clinicians were exposed to 
pharmacogenetic testing through representative who came to the clinic or gave 
presentations at dinner meetings. Clinicians in this sample also learned about 
pharmacogenetic testing on their own through continuing education classes through 
online resources and conferences. In addition, one clinician reported that she learned 
about pharmacogenetic testing from social media by joining a private Facebook group for 
Psychiatric Nurse Practitioners.  
Training Received on Pharmacogenetic Testing 
 Clinicians consistently reported that they did not receive formal training on how 
to use the pharmacogenetic testing in clinical practice. However, many clinicians 
reported that pharmacogenetic testing representatives provided information on obtaining 
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samples, billing, the usefulness of the test, and interpretation of the test. Clinicians 
reported that the pharmacogenetic company also provides access to geneticists and Pharm 
D’s who are available to answer any questions regarding interpretation of the 
pharmacogenetic results. However, many clinicians stated that they have not utilized this 
resource. Most clinicians believe that the reports are easy to read and interpret the results. 
Many clinicians believe that they learned more from colleagues who had been using the 
test than from other sources. Some clinicians are learning on their own by seeking out 
educational conferences and courses on pharmacogenetic testing. 
Factors Considered in Decision-Making 
 Clinicians in this sample discussed multiple factors that affected their decision to 
order pharmacogenetic testing on patients.  Some clinicians felt that pharmacogenetic 
testing should be used for everyone, while others only ordered testing if they believed it 
was warranted. For example, if there was a medical reason or if there was a strong family 
history of mental illness. Additionally, some clinicians found the test to be beneficial 
among patient who were adopted and did not know their family history.  Factors that 
affected decisions to order pharmacogenetic testing included cost of the test, benefits of 
the test, medication naïve versus medication failures, and severity of mental illness 
among patients. 
Cost 
 The majority of clinicians in this sample considered the cost of the test a major 
factor in deciding to order the test. Several clinicians believed that it is not cost effective 
to order the test on everybody. One clinician stated, “I think it would be a great the thing 
to have on everybody.  It would be irresponsible at this juncture to just randomly order it 
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on everybody.” Another clinician stated, “I generally don’t do it for anybody who doesn’t 
have insurance because it’s several thousand dollars”.  
 Clinicians found that government payers such as Medicare, Medicaid and Tricare 
covered the pharmacogenetic testing. However, private insurance payers did not cover 
the test. Clinicians reported that the pharmacogenetic testing companies provided a 
sliding scale for those who had private insurance. Most clinicians found the sliding scale 
to be reasonable and ranged from $20 to $330 depending on annual income. Clinicians 
found that most patients are unable to afford the test if they are paying cash for the test. 
Another clinician stated, “So it’s quite expensive still for commercial insurance. So, it has 
to be clinically relevant for that. But for Medicaid and Medicare population, I would do it 
all the time.” The majority of clinicians in this sample were less likely to order the test if 
patient is cash pay or has private insurance. 
Benefits of Pharmacogenetic Testing 
 The benefits of pharmacogenetic testing was another major factor that influenced 
clinician’s decision to order pharmacogenetic testing. The majority of clinicians believe 
that the test is beneficial to both the provider and patient about 90 to 95% of the time. In 
this sample, clinicians found that treatment guided by pharmacogenetic testing was not 
only useful as a guide for prescribing medications but also lessened patient’s fears and 
anxieties about medication, validated patient’s experiences with previous medication 
trials, and improved tolerability and adherence of medications among patients with 
mental illness. 
 Lessen fears and anxieties. According to the clinicians in this sample, there are 
many benefits to using pharmacogenetic testing. One of the major benefits reported by 
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clinicians in this sample was that the utilization of pharmacogenetic testing may lessen 
patient’s fears and anxieties from medications. A clinician stated that there was “a 
translation of folks from anxiety and fears about their own experiences with medications 
or what they have seen on the news, go to the point where they’re actually able to get 
support with medicine that helps them.” Similarly, another clinician stated, “So, the 
people who are a little leery of medication just to start with, that seemed to have helped a 
little bit for their anxieties about being on medicine at all any way.”  
 Validates patient’s experiences. Another benefit of pharmacogenetic testing 
according to clinicians is the test provides validation of a patient’s previous experience 
with medications. One clinician stated, for patients with “problems with side effects or 
issues that they had, had a lot of times will be reinforced by this, that gives them a sense 
of validity for what the test results present.” In turn, patients are more receptive to take 
medications. Another clinician stated, “I have had many patients who have felt more 
comfortable making the step in incorporating and using medications once we have the 
pharmacogenetic testing completed, because they know we are not just throwing 
something at them and hoping it sticks because it does for most people.” 
 Improves tolerability and adherence of medications. Clinicians repeatedly 
reported that they found the utilization of pharmacogenetic testing improves efficacy and 
tolerability of medications among patients. One clinician stated, “Some of them may need 
a lower dose increased and if they metabolize too fast they might need high doses to 
achieve efficacy. And then some of them they have genetics, genes and they say they 
don't metabolize or have inhibitors of this or that, they can have more side effects.  So, it 
helps with that to try and reduce side effects too as well based on the interpretation and 
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the testing is how it breaks it down.” Similarly, an additional clinician reported, “we may 
have made a better, more appropriate choice of medication and tolerability may be higher 
because of what our choices were.” Another clinician believed that pharmacogenetic 
guided treatment “improved medication adherence”. Overall, clinicians perceive that the 
pharmacogenetic test provides many benefits and is an additional resource or tool used to 
narrow down the options of medication choices when treating patients with mental 
illness.   
Medication Naïve versus Multiple Medication Failures 
 Another deciding factor for clinicians in ordering pharmacogenetic testing was 
whether or not a patient was medication naïve or had multiple medication failures. There 
were several conflicting views among providers regarding this topic. The majority of 
clinicians in this sample agreed that patients who had experienced multiple failures of 
medication trials were excellent candidates for pharmacogenetic testing. However, some 
clinicians are considering pharmacogenetic testing earlier in treatment. One clinician 
stated, “I would say many times the test have shown that what I already knew to be true 
was that they aren’t going to respond to all these different medicines because they’ve 
already tried it, maybe I should start doing it earlier in the treatment which we have 
started to do.  Thus far I kind of used it as the last resort because those are the people I 
thought of first to try it on. Because they are having such a hard time finding medication 
that would work, but now I’m starting to do it on the ones a little bit earlier.” 
 Medication naïve. Approximately 18% of clinicians in the sample believed that 
everybody should be tested and would benefit from the results including patients who 
have never tried medications.  One clinician stated, “I haven’t had, never seen anybody 
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that I thought didn’t benefit, somewhat from having the testing. Even if all it does is show 
that you’re on the right medicine at least we know that.”   
 Additionally, providers who are seeing adolescents and children were more 
favorable to ordering pharmacogenetic testing earlier in treatment. One clinician stated, 
“And that’s pretty much my rule with someone that’s that young and never been on 
medications never really had major issues that they really having some significant 
depression. I just don’t think that it's something we need to even wait on.” Similarly, 
another clinician reported, “I utilize in situations where -- even in the medication naïve 
patients, patient who has never been on medications.  If parents were exceedingly 
cautious, exceedingly anxious about – I think they are on this medication for the first time 
and I don’t want my kid to be a Guinea pig, I've heard that a lot through the years.”  
 Multiple medication failures. Most clinicians in this sample, considered 
pharmacogenetic testing for patients who had multiple failures of medications. One 
clinician reported, “I would not order this if they had a response to either the first -- one 
of the two or three medicines I tried – a certain logical sequence. So, if they had a 
response, I’d probably not get the testing.” The same clinician reported that he has “only 
been using it for patients who use at least two antidepressants or two mood stabilizers or 
two antipsychotics at therapeutic doses.” Similarly, another clinician stated, “Usually I 
order for patients who have failed at least – usually three different medications for the 
same diagnosis or the same set of symptoms”. While another clinician agreed, “I 
generally save it for ones that have failed three or four trials of medicine.” 
 Another clinician reported, “Well, so often patients show who have finally got to 
see me and have probably been on the same medication by the time they get to me. And 
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they’re either really frustrated and it’s almost like this still isn’t working and… or it’s not 
working the way that it used to work and I’m not quite sure where we need to go so, and 
that’s a good sign too.  So, I say, “Okay, instead of just going on a wild goose chase 
trying to figure out where we go next, you know why don’t we be a little more scientific 
about it now and go ahead and do the pharmacogenetic testing?”.   
 Clinicians consistently agreed that they are more likely to order pharmacogenetic 
testing when patient’s report that they have been on medications for years with limited 
response. One clinician stated, “I mean again like I find the most effective population to 
be the people who have repeatedly failed different medication trials.  I mean and the 
reasons for that can obviously be complex, but I think in those patients it helps to give 
them a renewed confidence in the treatment process.  Sometimes people come to me, you 
know I’ve been depressed for 20 years, I’ve taken like 15 medications and nothing ever 
helps.  I think nothing is ever going to help.  So, I’ve found that to be like a really great 
tool for those kinds of patients.” 
Multiple Adverse Effects 
 A substantial deciding factor for ordering pharmacogenetic testing was if the 
patient experienced multiple adverse effects from medications. One clinician stated, 
“primarily I’ve been using it for people who have tried a couple of different medicines 
and they didn’t work or they have had side effects and couldn’t tolerate anything and you 
know get testing, at that point and see if we can optimize their treatment.” Similarly, 
another clinician reported, “There is several things that tell me that I probably need to 
look at genetic testing. First would be had they had some strange reactions to medications 
either medicines don’t work for them or they get very sensitivity reactions they get 
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maybe get side effects or average effects that would normally be seeing as the dose was 
too high for example.” Clinicians in this sample found that the pharmacogenetic testing 
report was beneficial in understanding why patients were having adverse effects. 
Clinicians in the sample concur that adverse effects are a major deciding factor in 
ordering pharmacogenetic testing.  
Severity of Mental Illness 
 
 Another deciding factor in ordering pharmacogenetic testing among clinicians is 
the severity of the mental illness. Clinicians were more likely to order pharmacogenetic 
testing for patients who had multiple hospitalizations, chronic serious mental illness, or 
required higher doses of medications with limited response. One clinician reported that 
they are more likely to order pharmacogenetic testing depending on the severity of 
symptoms, for example if the patient “couldn’t get out of bed or couldn’t function.” 
Another clinician reported, “If somebody has had significant adverse reaction certain 
kinds of medicine or if they express frustration with medicine, if they express that, they 
feel like they're being treated like a guinea pig it tends to – even them out a lot more.” In 
addition, clinicians were more likely to order testing if patients required multiple 
hospitalizations for their mental illness.  
 The majority of the clinicians agreed that they would not order pharmacogenetic 
testing if a patient was responding well to their medication without any significant 
adverse effects of the medication. Most clinicians believed that pharmacogenetic testing 
should be used only if medically warranted and not for everyone. One clinician stated, 
“It’s not very often that I recommend it for someone brand new unless they specifically 
request it because I don’t think the testing should be a substitute to clinical judgement 
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also.  And what I certainly try to point out to my patients is that the testing it’s not being 
used for diagnostic purposes and that’s why with the new patient that at first you got to 
try to get a sense of what your working diagnosis or diagnosis might be.  So, if that’s the 
case, then I’m not necessarily rushing to get the genomic testing done, I want to see if we 
are on the right track based on what the assumed diagnosis might be before we all start 
thinking about that.”  
Perceptions of Clinicians 
 Overall, clinicians in this sample perceived pharmacogenetic testing to be a 
valuable tool in their clinical practice.  One clinician stated that pharmacogenetic testing 
allows “prescribers to make more educated decisions and more educated 
recommendations.” Another clinician stated, “I’m using it more and more as I become 
more comfortable with it and have seen more success with it that I do it a lot.” This 
section will discuss the impact of pharmacogenetic testing on clinical decision-making, 
how clinicians perceive shared-decision making in conjunction with pharmacogenetic 
testing, and populations who do not benefit from pharmacogenetic testing.  
Impact on Clinical Decision-Making 
 Clinicians have conflicting views on the impact of pharmacogenetic testing on 
clinical decision making. Most clinicians found that pharmacogenetic testing can positive 
influence clinical decision-making by providing reassurance to the clinician and patient, 
explain why patients have been resistant to treatment, reduce trial and error, and give 
permission to go beyond normal prescribing practices. However, some clinicians in the 
sample reported that pharmacogenetic testing could negatively impact clinical decision-
making in certain situations.   
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Reassuring to Clinician and Patient 
 Most clinicians found pharmacogenetic testing to be a significant piece in clinical 
decision making. First of all, clinicians believe that the testing is reassuring. One clinician 
states that the test is “reassuring that what we’re doing is on the right track and then we 
just need to tweak the dose up or down sometimes”. In addition, patients were also 
reassured by the results. Another clinician stated, “it sometimes just kind of helps to 
clarify like why patients haven’t done well which is also reassuring for them like I had a 
patient recently who you know had not – had good affect with a whole variety of 
medications.  And when we got their testing back, all of them were on the – do not – for 
lack of a better term do not use list.  Then they – so then they felt oh, it wasn’t in my 
head.  Like there actually seems to be indication that these weren’t very good 
medications for me in particular to take.”  
Resistant to Treatment 
 Many clinicians found that pharmacogenetic testing was helpful to explain why 
patients were resistant to treatment. One clinician explained, “it’s sometime interesting to 
see patients that have been on five or six SSRI’s, which I mean should be kind of 
questioned to begin with anyway, but then you know that they get this list of basically all 
SSRI’s in the red column so to speak.  And I see that this is why that sometimes patients 
are more resistant to treatment and can make, it can explain why, sometimes we get this 
niche and the patients are difficult and then we get results back that confirmed that they 
just don’t metabolize medications in a way that we would expect.” Similarly, another 
clinician found that “there has been a couple of cases where the child did have kind of a 
lot of metabolic issues and it did sort of explain why they hadn’t done well on past 
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medicines.” Clinicians have found test results to be consistent with clinical findings. One 
clinician stated, “I thought it’s really helpful and I have seen it a lot of correlation 
between medication that they have told me in the past that this didn’t work or it would 
make them miserable and you know that’s pretty consistent, not always, but you know I 
have learned that I can rely on those, and also I think they have a better success rate with 
the medication.”  
Guessing Game 
 Clinicians in this sample believe that pharmacogenetic testing has positively 
impacted their clinical decision making. One clinician stated, “Yeah I wouldn’t keep 
doing it if I didn’t see it was beneficial.  So, clearly I’ve seen results with my patients.” 
Several clinicians reported that pharmacogenetic testing reduces trial and error and takes 
away the “guesswork”. One clinician described it as the following: “And what will 
usually happen is doctors use medications that they think are safe, appropriate to the 
diagnosis if they had success with other patients, but everyone is different.  So, what 
works for one patient may not work for another.  So, usually it’s just kind of a guessing 
game.  You’re picking something out of a hat.  You keep picking out of the hat until you 
find something that’s good enough. And then you generally stop looking, but is that the 
optimal medication for the patient, you know is there something else.  If you would have 
tried three more things, would you have found something that worked even better.  I 
mean, who knows unless you’re going to do that, but who wants to put a patient on 35 
medicines and then pick the best one.” Another clinician stated, “I think it’s beneficial for 
the patient if for no other reason than it often times makes them feel like we know what 
we’re doing and we’re not just guessing.” An additional clinician reported, “It makes 
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their chance of showing – of no showing to future appointments a lot less because it gives 
people more hope that we’re not taking a guess at what types of medicine, we have an 
educated guess.” Overall, clinicians believe that pharmacogenetic testing provides them 
with an “educated guess” rather than the traditional trial and error approach and may 
reduce the timeframe to achieve stability with medication.  
Going Beyond Usual Prescribing Practices 
 Several clinicians reported how pharmacogenetic testing impacted their clinical 
decision making by giving them permission to go beyond their normal choice of 
treatment. For example, one clinician stated, “Also because – specifically because of the 
serotonin transporter marker. It sort of forces me to consider non-SSRI medications and 
in young people more then I probably would if I did not have the genetic testing 
available, because typically you know SSRI’s you know more well studied in young 
people or in many – not all that do have FDA indications in minors. And you know, so 
just classically you know have always – not always but majority of the time you know 
use SSRIs first line for both anxiety and depression and anyone under the age of 18 as 
opposed to an SNRI Wellbutrin or something. And so having done this testing has sort of 
opened my eyes to how many people are likely be co-responders to SSRIs because of the 
serotonin transporter and so I'm sort of considering non-SSRI medicines probably early 
in the course of – earlier in the course of treatment now than I would. But certainly, has 
been beneficial to me in terms of you know helping steer my prescribing practices in a 
direction that I think is more beneficial to my patients."  
 Another clinician stated, “And so sometime you know thinking outside the box 
being what I consider relative new to practice there are some meds that I just don’t go to 
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because I’m not as familiar with them. They are not as readily used and it’s kind of 
forced me to learn more meds and step outside of my comfort zone a little bit when I’m 
prescribing because they are indicated as being somewhat helpful to the patient and they 
are things that haven’t been tried before. And so that to me has been a little helpful 
because I don’t necessarily think about some of those medications…so that has helped – 
that has helped me and forced me to kind of move outside of the standard you know, you 
know the SSRI’s, the SNRI’s for depression and that type of thing you know.” Additional 
clinicians found that they were more likely to increase doses of medication if the patient 
was found to be a fast metabolizer of medication, whereas, they would normally be more 
cautious about doing so.   
Not Always Helpful 
 Approximately 25% of clinicians were unsure if changes guided by the 
pharmacogenetic test made a significant difference in clinical decision making. For 
example, one clinician who had been using pharmacogenetic testing for about six months 
stated, “I’m not sure the changes that we make have made that much different. I had one 
lady that – a couple of other things she was on was fine. And then we made another – I 
think we got her off Seroquel and put her on Remeron or something like that or 
Trazodone or something. And it didn’t work as well. But she felt better about it because 
she would gain so much weight on Seroquel anyway. She wasn’t really sleeping that 
great on it. But I think she was sleeping better on Seroquel than when we made the 
change. So I get a little confused sometimes – I’m not sure that it’s great as what I 
thought it was going to do when we first started. But I think the jury is still out. I haven’t 
been doing it long enough really with enough people to see.” The same clinician has 
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found it to be beneficial in some cases, he states “But it’s helped me guide me in a couple 
of cases. I’m being more open to it.” 
 Another clinician found that the results were not as helpful in clinical decision-
making when the results revealed tolerability of most medications. For example, one 
clinician found that in adolescents and children, “the majority of the time that kind of, the 
report might show that tolerate every medicine fine, as far as being able to metabolize it 
and maybe they just haven’t done well on medicine because they had just side effect for 
what not.” In contrast, a clinician who has been using pharmacogenetic testing in practice 
for one year stated “I have found helpful most of the time that probably about 75% they 
say this and this didn’t work and had bad side effects. The testing does correlate with that 
pretty good.  It's spot-on with it.” Another clinician perceived that the test was accurate 
50% of the time. This clinician reported that the test has “helped in a couple of cases, but 
it’s not been life changing.” 
 Some clinicians found that the medications that were suggested may not be 
clinically indicated for the symptoms or illness that the patient is experiencing. For 
example, one clinician stated, “even in the green column the medicine might not help 
their symptoms.” Another clinician reported, “Just because the medicines that they 
suggest like on the Genesight panel, on the psychotropic panel for example will show all 
of the antipsychotics, all of the anxiety medicines, all the antidepressants and typically, 
I’d say about 10% of the time, it’s – like most of the time it’s very bad side effects to a 
medicine. It will show up as a potential medicine that they should avoid. The other 90% 
of that medicine may be listed of like a green or caution. So clinically it’s sometimes 
frustrating and it doesn’t you know it’s not an exact science and I understand that and all. 
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Sometimes it’s frustrating because the data doesn’t support the way that the patient is 
reporting the way the medicine makes them feel.”  Another clinician stated, “I am willing 
to recommended for patients who I feel would benefit from it. But I don’t know. Based 
on my experience, I don’t want patients to have their hopes high and then get frustrated.”   
 An additional clinician found the test to be less helpful in patients who already 
know what works for them. This clinician stated, “It’s been some rare occasions when it 
wasn’t helpful and I don't feel it's just been based off the test.  I think it's just been off the 
sense of importance of what the patient has been saying and what they think works for 
them and what they don't feel like works for them, like I’ve when patients say okay, I 
don’t care what GeneSight testing?  This is what I know works for me, so.” Although, 
these clinicians continue to utilize pharmacogenetic testing to guide their treatment, there 
are still some uncertainties about the impact on clinical decision making and outcomes.  
 Despite concerns about the impact on clinical decision making, many clinicians 
believe that the test is beneficial for many patients in their clinical practice. One client 
stated, “I wish I could just do it for everyone, because I my motto is do no harm.”  I’m 
not into you know needle assessing and if where practicing the medications and we’re not 
really sure how the body is receiving that medication, that to me seems inefficient and, 
and it’s just not the best practice.  So, I know it’s just a you know a probability thing. I 
know it’s not a you know an absolute scientific way to know what method would work, 
but at least to eliminates a lot of the ones that aren’t going to work.” The majority of 
clinicians believe that the test provides insight on how to approach patients and avoid 
wasted time and unwarranted suffering for patients. One clinician reported, “It’s worked 
for me, it works that’s why I keep using it.”  
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Shared Decision-Making 
 Clinicians views on shared decision-making varied within the sample. The 
majority of clinicians utilized shared decision-making in their clinical practice and found 
the pharmacogenetic test to be a tool useful in the implementation of shared decision-
making. However, many clinicians reported that they would implement shared decision-
making with or without the test. Most clinicians viewed shared decision-making as a 
team effort and implemented shared decision-making through open dialogue, giving the 
patient treatment options, and clinical judgement.  
Open Dialogue 
 Clinicians believed that it was important to discuss side effects of medications, 
listen to the patient’s concerns, review previous medications, and explain clinicians’ 
recommendations. Most clinicians engaged in open dialogue with the patient to discuss 
treatment options guided by pharmacogenetic testing to develop a mutually agreed upon 
treatment plan. One clinician described the process as the following, “What I usually do 
when I show it to them is that I try to explain that the differences of the medicines that 
state that they are that are listed and it might possibly work and I try to give them some 
information, accurate information about those medicines and then help and then they can 
help me figure out which ones that they want to try first.”   Similarly, another clinician 
stated they implemented shared decision-making “by having a dialogue with the screen 
up and asking open-ended questions like what do you think we can try this and what do 
you feel.  So, I use a lot of those kinds of questions from the beginning.  I also at times 
will show them the documentation and tell them what I’m going to document.  And if 
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that’s okay with them, do they feel that that am I getting it, just right?  I use that word a 
lot, does that sound, right?  So that's how I use shared decision-making.”   
 Another clinician discussed how shared decision-making helps to build rapport 
with the patient. This clinician stated, “Absolutely because – yeah, because we're both 
really excited to get the results and I like take a look at it and we kind of bond about oh 
well no wonder that didn’t work or no wonder you couldn’t tolerate that – there it is right 
there, you know. So, I think it really does facilitate that relationship even more.” In 
addition, shared decision-making allows patients to feel comfortable asking questions. 
One clinician stated, “And they know I’m always open to them asking me questions.”  
Giving Patient Options 
 The majority of clinicians believed that it was important to give the patient 
options in treatment. One clinician stated, “I think 90 percent of the patients like that and 
I think a few are looking for someone just to tell them what to do.”  Another clinician 
stated, “Yeah, we look at the test results and say okay what do you think – I’m very 
collaborative with my patients and say do you think this means something. Do you want 
to try a little higher dose you know most of the time the higher doses mean – more side 
effects and I’m like do you want to try a higher so you metabolize it fast or do you want 
to try something different.” 
 In addition, clinicians want the patient to be comfortable with the treatment 
decision. One clinician stated, “It’s a big thing, it’s a big thing because I will make the 
comment at times I'm like probably several times you know we will come, you know 
we’ll get together with this test and decide what you know I offer you my 
recommendation and you see how you feel about that because you are the one going to be 
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taking the medication and you need to be comfortable with the decision, that we have 
come to.” Another clinician stated, “You know actually – that's my whole model is very 
collaborative and with my patient and their families, sometimes their family likes to come 
to and participate and helping the patient make a decision.”  
 Similarly, another clinician stated, “I mean I always tell my patients from day one 
that I see treatments as shared process period, because if they’re not happy or 
comfortable with their treatment then obviously I feel like we’re not having an effective 
therapeutic alliance.  So, I don’t know that it really enhances it that much.  For me other 
than the fact that you know I just try to present it as one more tool that I’m bringing them 
so that we can make the best possible decisions for their treatments together.” Overall, 
most clinicians believe that although the clinician is the one who provides the patient 
with the treatment recommendation, but the patient decides if they want to take the 
medication or not. 
Clinical Judgement  
 In addition to giving the patient treatment options, many clinicians agreed that the 
final treatment decision-making should be based on the clinician’s judgement and 
expertise. One clinician stated, “I think it is important that the final decision-making has 
come down to the prescribers’ judgment.”  Although many clinicians in the sample 
agreed that the final treatment decision is based on the clinician’s clinical judgment, the 
clinicians emphasized the importance of explaining their rationale to the patient.   
 For example, one clinician stated, “I basically, review the results and make my 
own decisions about what the direction would be -- I mean I explain those – explain when 
I’m changing medicines, why I’m doing it. So, part if that discussion is well -- it looks 
 70 
 
like you didn’t respond to any of these medications in this class. Maybe we just haven’t 
found the right one yet. Or the reason that we switch to another class -- I try to explain 
that. But that I would do that with genetic testing or not.” Similarly, another clinician 
stated, “I’m a pretty easy-going guy. I don’t, obviously prescribe whatever the patients 
want but I am very transparent with them. And I educate them fully before I make any 
medicine prescription and I tell them all the side effects. I’ll explain the neurotransmitters 
I explain why the medicine is working of them. I’ll explain them what their diagnoses are 
and I think – generally the patients respond to me pretty well because I’m very open with 
them, and straightforward and the genetic testing is no difference there.” An additional 
clinician stated, “you know they need to be included, they need to be feel like they are 
empowered in that because it is them it's, it’s, it’s wrong to welcome to testing for them 
and we’re going over it, before I explain the test in office. I say, “now are you feeling 
comfortable? You see what the medications we are looking at here.” And I will tell them 
the rationale of why I'm looking at maybe two or three particular medications.”  
Populations Who Do Not Benefit from Pharmacogenetic Testing 
 While most clinicians believed that pharmacogenetic testing was not 
contraindicated for anyone, clinicians were able to identify persons that may not benefit 
from such testing. On clinician stated, “I haven’t had anyone that I would say I didn’t 
think would benefit from it. But I haven’t, like I don’t use it on everyone who walks 
through the door either.” However, several clinicians agreed that patients who were stable 
on current medications, medication naïve, preferred alternative treatment, or persons with 
cognitive distortions or personality disorders were not ideal candidates for 
pharmacogenetic testing.   
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Stable on Medications 
 
 Many clinicians believed that patients with a straightforward diagnosis or stable 
on their current medications would not benefit from testing. One clinician stated, “I think 
that that’s a kind of jumping ahead of it and depending on the expense might not be 
worth it.  I wouldn’t do it on someone that was doing well on medication and were stable 
and there was no need to change.” Another clinician stated, “Typically I’m not going to 
do genetic testing on the person that comes in and I make a diagnosis and send out a 
treatment plan and they respond to that treatment plan.  I’m not going to do genetic 
testing on them.” Most clinicians believed that if the patient is doing well with the current 
treatment plan then it would unnecessary to perform pharmacogenetic testing.  
Medication Naive 
 In addition, many clinicians believed that patients who were classified as 
medication naïve would not benefit from testing. One clinician stated, “Well, again if you 
have somebody coming in and you know, they’re straightforward, maybe their 
medication naïve, this is the first time having any, any, you know first time seeing any 
provider for depression say or anxiety.  You know, I’m not going to rush right out.  I 
don’t think those people, would they benefit?  I think they would, but it doesn’t make 
sense at this point in time to spend their money nor are they likely to spend the money to 
do the testing if they haven’t had any complications.”  
 Another clinician with similar views stated, “I don’t necessarily give it to people 
who are treatment naïve and just walk in through the door.  I know the genetic companies 
tell us that will improve their treatment but you know lots of times, you know whatever 
we give them doesn’t necessarily change our treatment that much. Let’s say you know 
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there is a kid with ADHD who comes in and you have to pick which stimulant to use they 
are pretty much metabolized the same way and they come out in the same column on the 
genetic testing and they wouldn’t have it’s not in a genetic test and tells us that they’re 
more likely to cause a side effect.  The first-line treatments that their Medicaid plan 
covers, we still have to start with trying them. You know, there’s no point giving testing 
to everybody who walks through the door considering all the side effects, I think.”  
 An additional clinician stated, “So, a lot of them are naïve to medicine when 
they’ve come and my chances of picking something that works is pretty good.” Another 
clinician stated, “And so the first time, you know they are a virgin to any SSRI’s and 
their depressed, I’m not going to do that. I’m going to use my clinical knowledge and 
symptoms and start them on an SSRI.  Or same thing starting Lamictal on someone who 
is cyclothymic, Bipolar Type 2. Yeah, no every patient does not need this.” Clinicians 
consistently reported that they would save the test for persons with previous medication 
trials and failures.  
Alternative Treatment 
 
 Several clinicians reported that it would not be feasible to order pharmacogenetic 
testing on patients who were seeking non-pharmacological treatment. For example, one 
clinician stated that she would not order pharmacogenetic testing for “people who don’t 
do well with pharmaco, pharmaco, pharmaceuticals you know who prefer natural things. 
And for them I would, and that’s a lot of my practice actually, for those people I would 
not even think about the gene testing, I would think of you know out of the box, or think 
about innovative care.  And I’d think about complementary alternative which I do 
anyway, I mean I do that with everyone. So, what I would do is try to refer them to 
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somebody who specializes in, in that area.  You know in homeopath, either homeopathy 
or osteopathy, or somebody acupuncture, somebody that does more natural medicine.”  
 Another clinician stated, “well I mean obviously if I got a patient that comes in 
and they we decide that psychotherapy is the route we are going right now, I don’t 
mention the test. I don’t even initiate the conversation about the test because they are one 
made it very clear that they are opposed to medication or that really isn’t that much of an 
indication for medication.”    
Cognitive Distortions or Personality Disorders 
 Several clinicians reported that they would not order pharmacogenetic testing on 
patients with disorders that may limit their understanding of the test. One clinician stated, 
“I would have to say the only patient that I would probably be hesitant in doing the 
testing would be one that really doesn’t have a grasp of what the testing is going to 
actually provide and how it translates into treatment.”  
 Another clinician stated that they would not order pharmacogenetic testing in 
someone with a personality disorder. This clinician reported, “Some personality disorders 
like, there wasn’t really a well-established mood disorder where medications in general 
wouldn’t be recommending or there are patients that probably might get false hope 
behind the results of a genetic testing.  But most of the patients I see have a mental 
disorder, so I guess there are patients using that had only personality disorders maybe.”  
 Lastly, some clinicians in this sample believed that patients with significant 
cognitive distortions and paranoia would not benefit from pharmacogenetic testing. One 
clinician stated that the patients are “paranoid about it, you know, what are you, are you 
practicing this on me trying to get something?  You know, I think it's again just paranoid 
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of what is it going to say?  It may be revealing something that I don't want to know.  That 
kind of thinking.” Clinicians found that patients with paranoia or cognitive distortion 
were more likely to refuse the test.  
Risk and Downsides 
 Pharmacogenetic testing may pose risks to the patient. Clinicians in this sample 
were able to identify several risks and downsides to pharmacogenetic guided treatment. 
Some major concerns among clinicians included lack of evidence, simplicity versus too 
scientific, medication barriers, cost of the test, and misinterpretation or misuse of the 
data. However, some clinicians believe that there are minimal or no risks to using 
pharmacogenetic testing in clinical practice. 
Lack of Evidence 
 Some clinicians believed that the evidence is still lacking regarding 
pharmacogenetic testing. Several clinicians found that the test is not 100% fool proof and 
there is still room for improvement. Clinicians found that the test can place them in an 
awkward position when the results are not consistent with the patient’s report and 
therefore, place doubt in the patient. One clinician stated, “Sometimes if you have a 
patient that has been successful on medication and then the results come back and it falls 
into the red category or whether it appears the medication should not be beneficial. I 
think it could potentially create doubt in the patients or can put the provider in a place 
where decision to continue a medication or stop the medication.”   Similarly, another 
clinician stated, “But there have been times when I kept patients on medications that at 
least from the testing appear should not be effective. And the fact that I have had patients 
that, you know, for example, one lady’s testing came back and you know the one’s in the 
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red column were the only medicines that every worked for her it did cause some weight 
but it was the only that ever worked for her and I would have never tried her on it if I 
knew it was in the red column probably. So, it’s not like 100% fool proof, I think.”  
 Another clinician discussed her concern about the lack of evidence in psychiatry 
for pharmacogenetic testing in patients with Schizophrenia and Bipolar Disorder. This 
clinician stated, “So, I have pretty sick patients, a lot of bipolar, schizophrenia and I think 
that the evidence for that population, it isn’t quite there yet. Certainly, if you’re going to 
go on evidence based right now, in psychiatry the evidence base is there for depression.  I 
think other illnesses, it’s coming along, but the duplication studies aren’t quite there yet.  
The strength of the evidence isn’t quite there yet which doesn’t mean that it doesn’t work, 
it just means the research hasn’t been enough to say definitively yet there is definitely a 
difference if you action this gene variations.  You know I work in community health , and 
that’s something that was important to me, because I do think the test has value and I 
think for the more vulnerable populations that have the highest burden of medical 
illnesses and disease burden and higher rate of homelessness and substance abuse that 
any type of kind of cutting edge technology which I think is how genomics is viewed 
right now that that is the population that should absolutely have access to this type of 
testing, but that’s not ethics solution of others. I think it has value for a lot of different 
people, but I don’t think the evidence – the research is not there yet today to suggest tests 
to everyone that walks through your door.”  
 Some clinicians are concerned about the efficacy of the test since there is lacking 
evidence and research on pharmacogenetic testing among different patient populations 
the evidence is not clinically applicable to some patients. Another clinician stated, “you 
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know if you look at some of the literature it says you know it’s not a 100% fool proof and 
if you use – I guess if you take it only at face value and only we'll prescribe what's in the 
green column and only if FDA indicated this dose or whatever. I think if you rely only on 
that and fail to exercise any type of clinical judgment that could be a downside to it.” 
Clinicians emphasize the importance of using clinical judgment along with the tool but 
realizing that the test is not 100% fool proof at this point.  
Simplicity versus Scientific 
 Some clinicians view the test as too simplistic while others view the test as too 
scientific. The reports from the different pharmacogenetic testing companies vary. The 
majority of clinicians in this sample used Genesight or Genomind for pharmacogenetic 
testing. Several clinicians reported that the Genesight test report is displayed using a 
“green, yellow, and red” column for medications and they like the simplicity of the 
report. One clinician stated, “I really like the GeneSight for now because they are kind of, 
you know genetics for dummies. (laughing) They have a green light status meaning that 
all the particular drugs in that category are metabolized normally. And then they have a 
yellow kind caution which you know, some of the medications that the patient might 
have trouble with, they are ultra-rapid metabolizers or ultra-slow metabolizers. And they 
have lots of side effects and things like that or the drug might not be effective and then 
there’s a red category for you know, more significant gene-gene interactions or I mean 
drug-gene interactions or drug-drug interactions. So, I try to avoid them.” However, 
another clinician using Genesight testing stated, “They do put footnotes to describe 
clinical considerations and the verbiages that’s used for describing what they have 
actually tested, but I think it is a little bit too scientific.”  
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 In contrast, other clinicians preferred a more detailed explanation and summary of 
the genes rather than the “green, yellow, and red” list of medications. One clinician 
stated, “Well I was originally trained on the Genomind profile and I like it that it is a 
summary of the genes and the results of the genes in the first two pages and I like to 
know what is the gene and what was the results because that helps me make decisions 
better. Rather than like with GeneSight you have to flip through the pages and then try 
and put together yourself as far as a look of all the variants or all the polymorphisms. So, 
I don’t like having to do that it causes me extra work and extra paper work. And I also 
don’t care for the red yellow green report because when you are working with genes you 
are not working with like a vitamin D level that there is a good or a bad. It's when you 
look at DNA it will only tell you what the body is capable of making. It won't tell you 
what the body actually make or if that gene is expressed. So that’s where the clinical 
judgment is to come in a clinical training and so I don’t care for the GeneSight or the 
Millennium reports because they, try to make the results, I don’t know genetics for 
dummies and I think it does the patient a disservice to do that. It's more scientific it isn’t 
meant to be look at the green column and that’s what you can prescribe for a patient 
because that’s not necessarily true.” 
 Clinicians have conflicting views on pharmacogenetic testing reports. Some 
clinicians prefer to look at the “green, red, and yellow” columns for list of medications, 
whereas, other clinicians prefer to look at the DNA and the science behind potential 
gene-drug interactions. However, all clinicians believed that clinical judgement should 
not be replaced by pharmacogenetic testing, but rather as a supplemental tool in decision-
making. 
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Medication Barriers 
 Several conflicts were identified with medications including the cost of 
medications and the off-label use of medications. The cost of medications was a major 
barrier and impacted many clinician’s decision to order pharmacogenetic testing for their 
patients. One clinician stated, “And one of the other thing that’s so important is we have 
to always keep in mind is how much will these meds cost these patients to make a switch. 
Because for example the only medication to show up would be desirable to brings users 
direct category, if those are medications that are not available in generic form and a 
patient is a self-paid patient, for example, and they have no insurance, anything like that 
then you might just be cost prohibitive for them to consider certain medications. So, I 
always have to keep that in mind too. So, I run into problems when, you know, the testing 
might show that they need a certain group of medicines and the insurance might not 
necessarily cover it and there’s an argument in favor of getting a prior authorization 
approved but sometimes it works and sometimes it doesn’t.”   
 Clinicians found that insurance may not cover the newer medications or off-label 
uses of medications even if these medications are indicated by the pharmacogenetic test 
findings. One clinician stated, “Sometimes it’s just the cost factor the newer medicine 
and we get some samples but that doesn’t really help because the samples are gone and 
then they have to go back to making their decision about paying for them if we make a 
change.”  Similarly, another clinician stated, “To be honest the Medicaid will not pay for 
off labeled medicines.  So, a lot of time the reports have all of these newer medicines that 
are out now, the Trintellix, and the Viibryd, and Pristiq. And all these things, but 
Medicaid will not pay for a child to take those because they’re off label. So, I cannot 
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even consider them even though if I were in private practice or a private insurance. I 
might even consider that, so I’m already very limited to these medications that are 
approved for kids. You know if I had a different population I could prescribe the off-label 
medicines. I just feel so limited by that, working with the Medicaid population and again, 
private insurance will pay for anything I put on prescription, they don’t care about that.” 
In addition, another clinician stated, “The first-line treatments that their Medicaid plan 
covers, we still have to start with trying them. You know, there’s no point giving testing 
to everybody who walks through the door.”  
 Most clinicians found it to be frustrating that insurance would only cover 
medications on their formulary despite pharmacogenetic testing results. Another major 
concern was the cost of L-Methyfolate or Deplin supplements. The pharmacogenetic tests 
provide results on folic acid conversion which is a supplement that has shown to improve 
depression among certain individuals who have a deficiency and need supplementation. 
One clinician stated, “Yeah.  I do think that there's some risks.  That is, you know, like 
with the folic acid conversion.  What’s the use of giving them the information and then 
that they can’t afford $40 or $50 every two weeks, every month of this supplement.  It’s 
not really conducive to do it or even to talk about it.”  
 Similarly, another clinician reported, “I've not had the. unfortunately I've not had 
the advantage of treating a lot of patients recently with Deplin because it is considered a 
medical food. And a lot of the patients who I treat have what we call PeachCare in 
Georgia. It is sort of like state funded program quasi- Medicaid. It’s sort of like a 
Medicaid but for kids who you know parents make too much money to get Medicaid but 
not enough money to get private insurance, sort of like that. So, you know so the cost 
 80 
 
unfortunately is a limiting factor for many people or just accessibility to Deplin. So, when 
I was in private practice I had the advantage of having pharmaceutical reps you know 
frequently coming into the office bringing free samples, so we had a rep who brought 
Deplin. So, you know I would often -- you know if I had someone who came back with 
significantly reduced conversion I would give them samples of Deplin to try. And many 
times, they would you know start to notice improvement particularly in depression 
symptoms. And so that was sell them on the fact that it was worth you know spending 
their own money out of pocket to buy the Deplin if their insurance wouldn’t cover it. 
Well, the downside to all of my patients, or not all, the downside is the majority of my 
patient having Medicaid and Medicaid CMO’s that it’s difficult to get them to pay things 
like Deplin. But the upside of it is that for those patients there is no out pocket expense 
for the testing for GeneSight …so they pay nothing. GeneSight is totally free for those 
patients.” Clinicians found that even with appeals, insurance companies still do not pay 
for the L-methylfolate supplements such as Deplin. Many clinicians thought it was ironic 
that the insurance company would pay for the pharmacogenetic testing but were not 
willing to pay for the supplement if it was indicated for the patient.  
Cost of Pharmacogenetic Testing 
 The cost of pharmacogenetic testing was considered a major downside of the test 
for most clinicians in the sample. One clinician stated, “I don’t order it as a matter of 
routine on a new patient.  Because it’s you know, it’s stopped by costs and you know, 
honestly, I think you should.  I think everybody should have genetic testing done.” 
Clinicians were less likely to order pharmacogenetic testing if a patient did not have 
insurance.  
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 However, cost was still a barrier for some clinicians even if patients did have 
insurance. For example, some clinicians found that some insurance plans only covered 
genetic testing for a specific diagnosis which may not apply to their patient. One clinician 
stated, “a concern for me about the testing where sometimes I think, it’s a challenge from 
a clinical standpoint is that, some of the testing companies require specific diagnoses for 
them to bill to insurance companies.  Medicare only covers the test if there is a 
depression diagnosis.”  
 Additional clinicians found that patients were receiving “explanation of benefits” 
from their insurance company revealing astronomical prices for the test and this caused a 
lot of anxiety for the patients. One clinician stated, “The only risk is financially where a 
lot of the patients before they get anxiety because they get a bill in the mail from the 
company which is like for $16,000 or something crazy like that. And they call the office 
in a panic and I always try to explain them at the time that I do the test. I found that it’s 
just a declaration of what their benefits cover. As far as their insurance company, that it’s 
not a bill.  But I've had some cases where they actually send the bill to the client. And 
then I have to call the company with the client in the office and they're in a distress mode 
and work out the billing situation with the company over the phone. And in all cases, it 
was resolved, but there’s still the inconvenience for me as the clinician ordering it. There 
is also is a stressor for the client.” Another clinician stated, “sometimes people are getting 
bills in the mail of $6000, $7000 for the whole panel and they obviously see a lot of 
Medicaid and Medicare clients and that’s almost a year’s income for them for a test. So 
that’s a very distressing you know event for them. But sometimes for whatever reason, 
they don’t process the insurance properly or something happens and the people don’t still 
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get a check or a bill – get a bill in the mail, it’s still very distressing.” Although, the cost 
of the test was corrected for these patients, the clinicians found the process time 
consuming and distressing for the patient.  
 Most clinicians agreed that they would not order the test for patients who do not 
have insurance since it can be several thousand dollars for cash pay patients. In addition, 
some clinicians believed that the co-pay for commercial insurance may be too expensive, 
which can be up to $330 for some tests. One clinicians stated, “Now that I work with 
mostly Medicaid/Medicare, I use GeneSight, but you know it’s $330 at least typically for 
a co-pay for commercially insured patient.  So, people are just, you know they, again I’m 
not selling it as a perfect science and I encourage people to do it, but not everybody wants 
to spend that much money on it.” Clinicians found that some people declined the test 
because they could not afford the “bottom line”. 
Misinterpretation of Data  
 Misinterpretation of data was identified by clinicians as a major downside or risk 
to pharmacogenetic testing. Clinicians were concerned that patients would have a 
misperception of the results, unrealistic expectations or clinicians would misinterpret the 
results. In addition, clinicians had significant ethical concerns about the test. 
 Perceived results. Clinicians were concerned that patients would perceive the 
results differently. For example, one clinician stated, “I think if the genetic testing is not 
carefully explained to patients, I think there could be, there is a risk for 
misunderstanding, misinterpretation of what the test actually tells people what it means.” 
Another clinician stated, “If they feel like its diagnostic or if they feel like it’s a dictate on 
what’s a medicine that they should use based on how it’s presented.” Similarly, one 
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clinician stated, “I think if a patient is led to believe that it’s a perfect that they can 
somehow find a perfect remedy by taking the test then that would certainly be a pitfall.” 
 Unrealistic expectations. Some clinicians were concerned that some patients 
may have unrealistic expectations of the results. One clinician stated, “A downside might 
be if patient that's like they are overly – has a unrealistically high expectation of you 
know how it will help them – but really that's probably the only thing and that's where 
you're you know good patient teaching comes in. I haven’t really had that issue, but I can 
see how that could happen.” Another clinician reported, “I think if a patient is led to 
believe that it’s a perfect that they can somehow find a perfect remedy by taking the test 
then that would certainly be a pitfall.  But I think that’s really up to the provider to ensure 
that accurate education is given on you know the nature of the test as well as its 
limitation.”  
 While other clinicians were concerned that clinicians were not interpreting the 
data correctly. For example, one clinician stated, “Only downsides I can see are 
misinterpretations of what the testing actually represents. Might be a medication in that 
red category that is the most appropriate medication for them but just with dosing 
adjustments, might be a significant consideration and that including, going above what 
would be considered an on-label dosing if they, if it’s indicated.” Some clinicians were 
concerned that others may not utilize the data by making appropriate dosing changes if 
indicated by the test if they interpret the “red column” as a “no-go” column and only use 
medications listed in the “green column”. 
 Ethical concerns. Many clinicians believed that some patients may be fearful that 
their DNA data would be misused by insurance companies. One clinician stated, “I mean 
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there may be down the road there are some issues with the testing results and the genetic 
stuff being misused by government or insurance or something but I suppose that is true of 
all the genetic substances accumulating.” Another clinician stated, “ I think in their 
insurance perspective as far as if information could be used or disseminated to insurance 
companies, which I know it from my understanding isn’t and can’t be. Then that could 
potentially provide insurance companies with the reason to not insure, have different 
rates based on certain genetic marker results. That would be a sort of a macro societal 
risk but for the individual, that would obviously impact them too.  Just I guess a little bit 
about what I was saying earlier with regards to potential misuse.  I would perceive this 
misuse of the information by insurance companies trying to find out more genetic 
information about patients so that they can kind of risk, stratify their patients and charge 
higher rates on certain people that may not be “good metabolizers” in term of person.”  
 However, another clinician found that the patients do have an option to have their 
DNA information destroyed after a specific amount of days if they are concerned about 
misuse of data. This clinician stated, “one of the things I like about this test is it gives the 
client the option to have their sample destroyed within 90 days, but I think kind of, I 
mean that’s just empowering to be able to say, I don’t need to do anything, but tell me my 
test and then you’re going to destroy my sample.  So, I think the risks are more kind of 
those policy type issues.” 
 Another major ethical concern of pharmacogenetic testing was how the patient 
may internalize the test results. One clinician stated, “I think so, I think it, I used to not 
think this but I think that our minds are so powerful and even like my like analogy of the 
hazmat suit I think it’s psychologically, I am starting to like rethink that like you really 
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want to talk to someone with a hazmat suit on or do we want to stress the epigenetic 
more, you know?  So, I mean even though like Genomind has the calcium channel ion 
test and you know and just from my perspective I found that people are more of 
Bipolarish with those Mets especially if they present with the mood instability.  But I 
mean how do you explain that to just like where they go, do you just use it for prescribing 
purposes?  I mean, I guess there are some questions are ethics that come in and turns of 
this is new science and it is so much more important than any genetic vulnerability that 
you have to be careful.”  Some clinicians were concerned about how to explain the results 
and how the results my affect the patient psychologically. 
Minimal or No Risks 
 Although several risks or downsides of the test were identified, most clinicians 
agreed that that pharmacogenetic testing had minimal or no risks to the patient. Many 
clinicians commented that there are no physical or medical risks since the test is a buccal 
swab and does not require a blood draw. One clinician stated, “You know, I don’t really 
see a downside, especially when it comes with their Cytochrome P450 pathways. I don’t 
see where a negative thing could happen you know knowing that you’re a poor 
metabolizer of 2D6. No immediate health risks.  Like I said it’s a buccal swab.” Another 
clinician stated, “I don’t see anything physical I think the emotional risk is getting 
affirmation so that’s a good risk I think.” Additional clinicians explained that as long as 
the patient understood the costs and that the test is “not an absolute that there’s no 
guarantee that this is going to be the most effective medication that if it’s explained to 
them that this is yet another tool among many to come up with the right medication for 
them then there is not really a risk.”   
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Patient’s Perception of Pharmacogenetic Testing 
 Approximately 89% of clinicians in this sample agreed that patients understand 
that usefulness of the pharmacogenetic testing.  However, most clinicians believed that 
the patient’s understanding depended on how the provider educates the patient. One 
clinician stated, “I think I’ve never, it’s rare that I have somebody who has unreasonable 
expectations of what it can do.  Occasionally I will and those tend to be patients just with 
a little lower education level who just maybe need more counseling and you know more 
repeated explanations to more fully understand it.  But I think patients generally get the 
idea of it.” Another clinician explained the process as the following: “Most of them get it 
immediately, no matter what their educational level they get that, it’s like it being a super 
sleuth you know.  And we’re looking for more information.  So, I think I’m being a little 
scientist or a little detective and you know I can be there with them, or we can look for as 
much information as we can possibly get to solve the mystery of who they are, and why 
they are presenting you know with symptoms that they have.  So, they get that and I think 
they understand that.  In fact, very often, I mean I don’t know how they perceive it but 
very often they’ll come back and they’ll say could my family, a family member being 
tested.” Most clinicians found that patients had a basic understanding of the test as long 
as the clinician took adequate time to explain the test and results. According to clinicians 
in this sample, several factors that affected the patient’s perception of the test included 
patient “buy in”, perceived effectiveness, and patient education.  
Patient “Buy In” 
 Clinicians believed that beyond the scientific aspect of the test, that there was a 
psychological aspect that influenced patient’s “buy in” to the test. Several clinicians were 
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surprised at how receptive patients were of the test. Clinicians believe that 
pharmacogenetic guided treatment increases patient “buy in” by giving patients hope and 
confidence.  
  One clinician stated, “Patients generally respond to it well, they like doing it.  It 
gives them some objective data to look at instead of just being so abstract and taking the 
medicine that they never heard of that they hope will help.  So, you know they get a copy 
of the report they can look at, go through it.  I think sometimes just having a patient have 
that in their hand and some objective data, it helps them have some hope that it will 
work.” Similarly, another clinician stated “I think a lot of people think that psychiatry is a 
lot of the guessing games, type of thing and we can get any more exact science to what 
people are experiencing, I think it makes them a lot more trusting in what we’re doing.” 
 Another clinician stated “So in this kind of situation like I said quite honestly, I 
feel not just for me in terms of my decision making and my medical recommendations. 
But I feel like it also gives the parents some level comfort I don’t know if that's the right 
word necessarily. But it gives some level of comfort or confidence that you know we’re 
hopefully going to be choosing from a more limited number of medications and hopefully 
for medications that are less likely to be ineffective and less likely to cause side effects.” 
Another clinician agreed and stated, “I think, I think there is a couple of things that come 
in and the play with the patient.  I think number one, if they have a higher level of 
confidence that they are not going to have side effects I think that plays into it a great 
deal.” Similarly, another clinician reported that the test was “not always a 100%, but it 
can kind of build the confidence in the patients.”  
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 Patient “buy in” was a major factor of a patient’s receptivity towards 
pharmacogenetic testing. According to clinicians most patients were satisfied with the 
results and were excited to have something scientific and concrete. Clinicians found that 
a written report helped provide hope and confidence to the patients about the clinician’s 
treatment recommendation.  Most clinicians agreed that the patients had a basic 
understanding of the genes and what medications would work best for them.  
Perceived Effectiveness 
 
 Clinicians found that how well the patients perceived the effectiveness of the 
pharmacogenetic testing impacted their outcomes. For example, one clinician stated, “I’m 
a big buyer into the pharmacogenetic testing because of the perceived effectiveness of it. 
But right about 10% of the it that I order it is I would say is very effective the other 90% I 
would say is not really clinically that relevant. And I don’t know, you know, it’s my 
personal experience that if a medicine that’s in the green column and the person has not 
tried it before and I tell them about the science behind the test. I don’t know whether or 
not that’s the test working or if it’s the placebo effect that we said first. I feel like their 
buy in is a little bit more, this is the scientific thing.  I would count that as worth 
something” 
 While another clinician stated, “I will say though with some parents, I feel like in 
some ways it has a little bit of a placebo effect. That they like the fact that the test and 
that’s something comes back with this report. And so much of mental health is not 
objective like that. And there are some parents where I feel like they maybe it didn’t help 
me a lot but it gave the parents that comfort and a belief that this medicine that was 
picked.  It’s going to be good for the child even though I totally explain that we’re just 
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looking how they metabolize the medicine not really the therapeutic effect of it, even 
though I’ve explained all these I feel like they will latch on to it and kind of have a 
positive view and if that makes any sense.” 
 Several clinicians mentioned the “placebo effect” of the test. Most clinicians 
agreed that there was a psychological component that this was a significant factor in the 
receptivity of the test. Some providers were unsure if the test was completely accurate or 
if it was the presentation of findings that resulted in positive outcomes among these 
patients. However, many clinicians agreed that the patient’s “buy-in” was worth it and 
patients did not feel like the clinician was just “throwing medications at them” but it was 
more of a scientific decision. 
Patient Education 
 The majority of clinicians in this sample believed that patient education was a 
significant factor in how well the patient perceived the test. Some clinicians thought it 
was best to keep the explanation of the test simple, while other clinicians believed that 
the patient would benefit from a more detailed explanation of the test. Clinicians found it 
helpful to explain the benefits of the test and also the limitations of the test.  One clinician 
stated, “I start out by explaining to them that the testing is not going to be a definitive 
tool. There is not a way to interpret that says just because you can metabolize this 
medicine normally and there aren’t any genetic variations in that, that it’s the right 
medicine for you. Explaining to the patients from the outset that we’re not going to get a 
definitive direction on medications from the testing has been helpful.” 
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Keeping it Simple   
 The majority of clinicians in this sample believed that the clinician should educate 
the patient in simple layman’s terms for the patient. One clinician stated, “I try not to be 
overly technical about it, but at least letting them know based on their own genotype what 
medicine might be more or less likely to respond to and what cautions we need to be 
aware of. Like for proceedings with certain ones that may be better lower doses or higher 
doses or might be more prone to the side effects.” 
 Another clinician stated, “And as far as metabolism, I don’t really go down that 
road.” Similarly, another clinician explained that test as the following: “I don’t go into 
every single gene, I don’t think that’s helpful to most patients.  I mean occasionally there 
are patients who are in the medical field who want to discuss in further detail and we 
certainly can do that at their request.  But in general, I just try to I explain the overall you 
know idea of the fact that it’s, it is taking, we’re getting a sample of your organic 
materials, that the lab can analyze these different genes and see how well they metabolize 
different medications. And then create the profile that can be helpful for us to guide us in 
the right treatment decisions.”  
 Most clinicians found the GeneSight test easy for patients to understand. One 
clinician stated, “Well, I mean, the results are pretty easily interpreted. The GeneSight 
made the medications in green, yellow and red column which they can somewhat 
understand.  I mean, it’s a little more complicated than that.  At least it’s something they 
can look at and understand.  If this is in the green column it’s more likely to work and has 
good results with less side effects. And then whether there might be some interactions 
and there’s some smaller and moderate risk that the patient won’t tolerate or potentially 
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have side effects from the medication is kind of like the yellow-light. And then 
medications that are very prone and more at risk and probably should be considered 
either and not to be used at or be discontinued if they are the already on and that would 
be more of a red-light scenario.  So, everybody can kind of use that visual and the results 
of the tests are set up and three columns or it’s pretty easy to understand now.”  
More Scientific 
 However, other clinicians believed that a more detailed explanation was necessary 
for patients. One clinician stated, “So, it could be pretty arduous task to explain it, it’s 
very complex ideas them but I think you have to try and so anyway. But for the most part 
I’ve have good success.  I have been pleased with the results.”  
 Another clinician found it important to explain the metabolism of medications, by 
stating, “I explain to them what that means that either their liver creates certain enzymes 
that specifically send certain chemicals to break them down and so that they be 
eliminated from the body and that some of them work more efficiently than others. And I 
try to stress to them just because they have, you know, a poor metabolizer of a certain 
kind of enzyme.  It doesn’t mean it doesn’t work at all.  It’s just means that it’s not as, it 
doesn’t do its job as efficiently as the one we usually, the normal one if you will. It works 
too well, you know, as an ultra-metabolizer, you just, it’s a worker bee it works so hard 
the medicine never actually gets into the bloodstream. It breaks it down before it ever 
gets circulating in the body, things like that.  But, I go through and tell them what that 
means you have a higher risk for this or a lower risk for this but it doesn’t mean you have 
are immune to it but you have a lesser risk.”  
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Knowledge Gap Among Clinicians 
 Few clinicians stated that they do not understand the all of the scientific aspects of 
the test. One clinician stated, “I do my very, I just do my very best to keep it as simple as 
possible. And I do go over every single page and I say if you want to know real scientific 
stuff about it I said you probably just have to call the lab and see what they have to say.” 
Some clinicians found that most patients just want to hear which medications to take and 
which medications to avoid.  
 Similarly, another clinician stated, “The phenotypes, the genomes makes me a 
little crazy so it's a little over, out of my league so I don’t, I don’t go over it, I don’t 
pretend know it all everything that’s on the test. Just getting to the basics.” An additional 
clinician stated, “Now some of the other stuff, you know, the CYP pathways I don’t even 
understand. They probably don’t either. But I tell them, if they want to call and get more 
information, the number is on there and just to call.”  
 Overall, there are different education styles among clinicians which may affect 
how a patient perceives the testing. Some clinicians prefer to explain the test in layman’s 
terms while others prefer to provide a more detailed explanation. Few clinicians reported 
a gap in knowledge regarding the scientific aspects of the test. Some providers choose 
their education style depending on the education level of the patient and their intellectual 
ability to understand. Some clinicians discussed test results in just a few minutes up to 
one hour depending on the clinician. Most clinicians reviewed the test and the patient’s 
previous medication trials before going over the test results with the patient and provide 
the patient with a copy of the test results.  Despite the different education styles, most 
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clinicians were confident that patients understood the applicability of the test and were 
favorable of the test.  
Application of Test Results Among Clinicians 
 Clinicians in this sample found pharmacogenetic testing to be applicable to 
patients with a variety of psychiatric disorders. Many clinicians reported that the test 
helps to identify problems with medications, helpful with prescribing and augmenting 
medications, and reduce trial and error among patients. Clinicians in this sample 
identified how they are using pharmacogenetic testing in current clinical practice to guide 
treatment decisions through medications in adults and adolescents with the multiple 
psychiatric disorders. 
Medications 
 Clinicians identified several ways that pharmacogenetic testing was helpful in 
selecting and dosing medications. One clinician stated, “I just guess picking the 
medication is sort of like finding a needle in a haystack I think of the testing as we’re 
moving a lot of the hay.” Clinicians were more likely to go higher or start lower doses of 
medications depending on test results and metabolism differences. Clinicians used the 
test to help them identify patients at risk for weight gain or side effects, inborn 
metabolism issues, dosing medications, and the impact of the test on patients taking 
medications that are structured similarly. In addition, many clinicians reported the benefit 
of the Methylenetetrahydrofolate enzyme in this patient population.  
 Weight gain, inborn metabolism error, and side effects.  Clinicians in this 
sample were able to use the pharmacogenetic testing to reduce side effects and improve 
tolerability of medications. Some clinicians reported that it helped them to identify if 
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someone was at risk of weight gain or side effects from certain medications. For example, 
one clinician stated, “With the long and short form of the serotonin transporter and then 
that variation at the 5-HT2C, you know I’ve had people tell me about weight gain and 
certainly the results of the test to forward that yeah, they are more likely to gain weight.” 
Clinicians used this information to reduce weight gain in these individuals. 
 Additional clinicians found the test to be helpful to identify if a person had an 
“inborn error in metabolism” that would affect their responsiveness or tolerability to 
medication. For example, one clinician stated, “x and y medications and the black box 
warning on Lamictal and the mood stabilizers it can direct on guidance in terms of 
knowing if someone possibly has an inborn metabolic issue that would affect their 
responsiveness or side effects profile to medication.”   
 Another clinician stated, “I had a lady. She was taking Paxil which I don’t like 
prescribing Paxil anyway because they tend to have a lot of side effects. But it’s an older 
Selective Serotonin Reuptake Inhibitor and she was saying whenever she took that 
medicine, she had brain shocks where she would feel like electricity was running through 
her brain. That Paxil is the type of medicine that once you stay on it, it’s hard to get you 
off it because you get the withdrawal. She was very afraid to withdraw off that 
medication, so she never stopped it. So, we did the genetic testing and I was able to 
convince her that with Paxil is listed here in the red. And we got her off that medicine. 
We started her on another medicine which was in the green which was Effexor XR or 
Venlafaxine she did a lot better.”  
 Dosing. More specifically, clinicians identified several success stories of different 
medications and how the test guided their treatment decision. For example, one clinician 
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reported, “I’ve had a couple of really fascinating cases one involving a pair of identical 
twins.  We did the testing on both of them and they came out identical. (laughing) Which 
was really interesting. You would sort of hope that would be the case (laughing) but you 
never quite know when you’re onto something.  But one of them had some kind of 
genetic variation or something like that.  And in their cases, they both tend to take high 
doses of the same medication actually and based on the genetic testing it kind of 
showed… no wonder they’re taking high doses because the testing was sort of indicating 
that they just might need to do that and that was very interesting.  I also had one instance, 
and not too long ago, where I had siblings where both siblings had testing done and it was 
as though certain aspects of it were identical, and other aspects which is completely 
different.”   
 Another clinician reported, “I have one lady that we had her on 120 of Cymbalta.  
And by the time she had taken the test, we changed her to something else. Well, we got 
the results, she that’s why the 120, still didn’t even work, you know, whichever it is, slow 
metabolizer, so therefore, for fast metabolizer, therefore, needed more. That’s why it 
didn’t work.”  
 Similarly, another clinician stated, “Well, I mean I’ve had a number of patients 
who were you know creeping up towards the higher end of dose ranges on certain 
medications and if they had testing done and it came back and indicated that this patient 
might need higher doses, then that was really helpful because that way as long as you 
were tolerating it okay, you felt a little more comfortable about going up towards that 
high end of a dose range and maybe even certain instances going a bit above it.” 
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 Similarly structured.  Clinicians also found that patients may metabolize 
differently two medications that are similarly structured. One clinician stated, “What I 
think was so fascinated too is about is that you can do the testing let’s say you’re on 
antidepressants and a patient will have, let’s say, Lexapro in the green category and 
Celexa will be in the red. It’s unbelievable, one is half the molecule of the other and with 
Pristiq and Effexor they can be so different and I try to point that out to the patients and 
it’s really amazing that it could be detected, that kind of a difference for medications that 
aren’t that structurally different from another.”  
 Methylenetetrahydroflate enzyme. A majority of the clinicians found the 
Methylenetetrahydrofolate (MTHFR) Enzyme information from the test to be very 
helpful in treatment. Clinicians discussed how MTHFR is a precursor to 
neurotransmitters and can affect depression in many individuals who have a significantly 
reduced folic acid conversion. One clinician described L-Methlyfolate as a “magic wand” 
and stated, “So, with the folate it’s seems like with this l-methylfolate is like this magic 
wand (laughing), you know is like okay successfully the body is better able to receive the 
chemicals where they need to go.  And so, when I have people who are really, really 
lethargic I think about a lot of things.  But I mean folates one of the things to think about, 
I think about B vitamins.  I think about a lot of things, but I also will just start them on a 
low, low, either medical food like Deplin or an over the counter. And so that’s kind of 
how I educate them about the L-methylfolate, and just to you know we only make one 
change at a time, so I don’t, I don’t change their medication, and some other nutritional 
thing and that folate, I’ll tell them just how to try this folate, for a week or two just begin 
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to just notice, some people notice that right away, just wake up the next day say oh my 
gosh my brain is working, you know I can concentrate.” 
 Another clinician stated, “Well I have actually just, I have one patient who only 
takes the supplement and she does significantly better. She also was able to, I don’t know 
if this is related at all, but she was able to stop smoking pot which she had been smoking 
every day. And she, and so I don’t, she thought it helped her get off marijuana so, but she 
and I did have her on an anti-depressant. Eventually I was able to just stop the anti-
depressant without any resurgence of symptoms whatsoever.” 
 Similarly, another clinician stated, “Occasionally, I’ll see someone where it’s 
pretty clear that they don’t need medicines and then they don’t get the test except for 
maybe the MTHFR test.  Yeah, I think it’s beneficial because we’ve known for maybe 20 
years or so that some patients particularly those with depression don’t respond very well 
to antidepressants unless they had supplementation with L-methylfolate and the people 
that need L-methylfolate are the people on the testing who fall either in the far right or 
middle ranges as opposed to the far left, which is normal. So, I find that probably how 
about equal numbers of people are on the far right or in the middle, excuse me the far 
right or the far left.  And then a whole lot of people are in the middle and so I would say 
about two thirds or something of the people that I tested I find an L-methylfolate 
supplement. And I think it helps.” 
 Most clinicians in the sample found the MTHFR information to be valuable 
information from the pharmacogenetic test. Clinicians reported that patients with a L-
Methylfolate deficiency are at higher risk of inflammatory disease including hypertension 
and cardiac problems.  However, some clinicians stated that they did not use this 
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information often in treatment due to insurance not covering the L-Methylfolate 
supplementation and the cost was a barrier for many patients. In addition, some clinicians 
reported that they were not convinced by the literature that supplementation was 
beneficial. One clinician stated, “I don’t really know much about that literature actually. 
My understanding is that there is some debate whether that folic acid information is 
actually a helpful. In the actual clinical setting that you do have to be severely folate 
deficient in my understanding to benefit from it.” 
Adolescent Population 
 Clinicians in this sample found pharmacogenetic testing to be beneficial in the 
adolescent population. Some clinicians were more likely to “think outside the box” and 
look at alternative medications that they would not necessarily consider after using 
pharmacogenetic testing. One clinician stated, “Typically you know SSRI’s you know 
more well studied in young people or in many not all that do have FDA indications in 
minors. And you know, so just classically you know have always, not always but 
majority of the time you know use SSRIs first line for both anxiety and depression and 
anyone under the age of 18 as opposed to an SNRI Wellbutrin or something. And so, 
having done this testing has sort of opened my eyes to how many people are likely be co-
responders to SSRIs because of the serotonin transporter. And so I'm sort of considering 
non-SSRI medicines probably early in the course of, earlier in the course of treatment 
now than I would. But certainly, has been beneficial to me in terms of you know helping 
steer my prescribing practices in a direction that I think is more beneficial to my patients. 
Often times go ahead and ordering the GeneSight testing, so that I’ll know okay is the 
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second SSRI trial worth it or should I just move on to an SNRI or Wellbutrin or 
something like that.” 
 Similarly, another clinician stated, “Well, there is one girl, she’s just an 
adolescent.  She’s maybe 15 and her mom is super, super anxious and she’s depressed 
and anxious, the child is.  But the mom is very anxious about medicine and I tried like 
two or three SSRIs with her. And she would have these like one of them she felt like it 
made her suicidal and then when she would just have that seemed to me to have extreme 
side effects whenever it was she felt weird or, or her stomach hurt but it seemed kind of 
extreme.  And so, I finally suggest that the test and it actually did come back, that she did 
not metabolize a lot of those as well.  And there was one kind of left on the list that she 
could metabolize on this list like Zoloft and then all of those new ones that are not 
approved for kids. So, to be honest I’m not sure whether it but she’s done better on the 
Zoloft, she’s been willing to take it and she has done better.  And I don’t know whether 
it’s really because she tolerates that or they just believe so much because they really liked 
getting this report. But doesn’t really matter to be because she’s taking it and she thinks 
she’s better.” This clinician was unsure if the test was accurate or if the patient was doing 
well due to a “placebo effect” of the test, however, the clinician was pleased with the 
outcome. 
 In addition, clinicians found that parents were eager to have the testing done on 
their children. One clinician stated, “Parents are looking for something for their kids. 
They want like some they want the best. They want the newest. It’s my kid, I got to give 
this big job, and so sometimes parents are really eager sometimes.” The same clinician 
discussed how “A woman was given the affirmation that she was right and the doctor was 
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wrong all those years and she’s in her 60’s, you know maybe 50’s and she has been 
receiving psych care for since her 20s.” 
 Another clinician found that the testing to be critical in adolescents who were 
suicidal to reduce trial and error. This clinician stated, “So but I did get to 17-year-old 
and I have one that even I had a male come in a while back he was having transient 
suicidal thoughts I did the GeneSight and that was the first thing we did was the 
GeneSight. Because I feel like that is extremely serious situations they’re much higher 
they are high risk for suicide you and I just don’t want to play around with medications in 
that kind of situation. Plus, their naïve to medications, we can do several trials you know 
and waste a lot time I thought it need to be addressed right then.” This provider believed 
it was crucial to order testing to find the best treatment possible for this adolescent.  
Autism and Non-Verbal Patients 
 Clinicians in this sample found pharmacogenetic testing to be beneficial in 
patients with autism or those who non-verbal. One clinician reported how she was able to 
identify a reduced folic acid conversion in a patient with autism and responded well to 
treatment. This clinician stated, “I had a new patient who had been treated in New York 
always only by a neurologist never a psychiatrist. And I think she was one of the ones 
that walked through the door for the first time that I did genetic testing on her because 
she's on the autism spectrum and a lot of the times they don’t respond the way you want 
them to the medication and I thought I’m not going to just start guessing. I’m going to do 
the testing and see what it comes back as and she came back, she came back deficient and 
so I gave her, we had samples of Deplin, and I gave her a couple of boxes of samples. 
And mom was like I see the difference and they can't afford it.” 
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 Additional clinicians discussed how they have found pharmacogenetic testing to 
be helpful in patients who are non-verbal. One clinician stated, “I have one client who is 
or he is in his probably late 20s and he is developmentally delayed and severely so he is 
non-verbal and his mother has been struggling to figure out what to do for him to calm 
down. He gets agitated playing about he can get, he can violent and she couldn’t find the 
right kind of medication for him and so she came, he came to my service after being 
around about the time or two. And I started, I told I started off by saying that why don’t 
we try this and she was you should have still look on her face. She is just is like oh my 
gosh this might be the miracle answer. And I reassured her might not be the miracle 
answer but it's another opportunity to approach his behaviors in a different way with the 
different kind of medication because maybe, you know,  maybe it's time for a change. So 
and I think that’s the main thing that makes me try it again and again and it's the fact 
people see some hope for progress with themselves or their kids so. I usually order it on 
patients who are having some kind of what,  two, two kinds of patients. First it will be 
non-verbal patients, I take care of a number of group home patients who are nonverbal. 
And I’m looking for any, most of them have been living in a group home, behavioral 
episodes, they are on six meds. They come to me and I try to get any kind of input I can 
get.” 
 Similarly, another clinician discussed how he was seeing a “non-verbal 21-year-
old was given a stimulant he was taking a lot of that, a lot of Adderall and just wasn’t 
comfortable with the dosing amount that he came to me. We did the testing, the testing 
showed he was fast metabolizer and that gave me more comfort to write for that med, the 
dose, doses.”  
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 Clinicians discussed how it can be difficult to treat patients who are non-verbal 
since they cannot tell you what is bothering them. The clinicians reported that they rely 
on the caregiver and their exam of the patient. Clinicians reported that the 
pharmacogenetic testing provides another tool to help guide medication selection in this 
population.  
Addiction Disorders 
 Some clinicians found it helpful to know if a person was a slow or fast 
metabolizer of medication in patients who had addiction disorders or co-occurring 
disorders. Clinicians reported that the test would help them to determine if they were 
drug seeking by asking for more medication or if they were truly a fast metabolizer and 
required higher doses. One clinician stated, “For the substance abuse population, it's been 
helpful.  To say hey, look, they will come back asking for more. This is how your body 
says you metabolize medication.  That's been helpful from I think the psychological state 
of I need more, it's not working, I'm still having cravings et cetera, et cetera.  So, it's 
helped me in that fashion to have some scientific literature to say hey, look, it's not a 
rationale to say that you would probably need to go with more or actually you need to be 
lowered, actually they could be split into your dose because you metabolize it too fast.  
So, it helped me to have that scientific support to say that and give them a copy of it to 
establish more of a common relationship and to say look, try to understand what I'm 
understanding my rationale in this decision-making here.” Clinicians found it helpful to 
have a scientific report and rationale for their decision. 
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Attention Deficit Hyperactivity Disorder 
 In this sample, clinicians had conflicting views about the usefulness of 
pharmacogenetic testing in children with Attention Deficit Hyperactivity Disorder 
(ADHD). One clinician found the test to be useful in a 9-year-old patient who had a 
disruptive mood dysregulation disorder and ADHD. The patient had not responded well 
to any medication and symptoms were not controlled. The clinician ordered 
pharmacogenetic testing and found that the patient does not respond to 99% of 
psychotropic medications. The clinician reported, “As of when I saw her earlier this week 
it helped me try to make a couple of changes and we started with the medications that 
gave the longest time to see any kind of effect. And just when, on Tuesday when I saw 
her just decided let’s change the stimulant because we haven’t been able to get the mood 
regulated. Let’s at least try to get her focused on for school. I haven’t had any phone calls 
yet, which is unusual…so it might have helped.”  
 In contrast, another clinician stated, “I had a kid who he was, it’s Concerta, was in 
the red category for him and supposedly for him per his mom and the teachers it was, it 
was really, really effective. But it should not have been because he was, he was supposed 
to have a reduced response on alpha receptor and on COMT so it was in the red category 
for two different reasons that basically he should not well on any stimulant. And he also, 
did not, was not sensitive to alpha so, and the alpha receptors. I couldn’t exactly, I 
couldn’t explain that scientifically if I wanted to but needless to say the reality was he 
was doing well.” Therefore, this clinician did not change the dose or medication since the 
patient was doing well. However, the clinician did state “I don’t see that a lot”. However, 
the clinician could not explain why the patient’s report did not match the testing results.  
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Anxiety Disorders 
 Some clinicians found pharmacogenetic testing beneficial for patients with 
anxiety. Clinicians reported that patients with anxiety are usually anxious about taking 
any medication and the test can increase patient “buy in”. One clinician stated, “So if I 
have a patient that comes in, very anxious OCD type and they had a reaction to one SSRI. 
Then sometimes, I use it more for patient buy in. Because I'm like well you know this test 
is a more objective way to let me know what your response would be, so that’s one. And 
then if I have patients who have become just very resistant to a lot of drugs that gives me 
a place to start.”  
 Another clinician reported how the test was able to guide dosing for a patient with 
anxiety who was experiencing side effects from a medication. This clinician stated, “So 
one example would be an older woman who is in her maybe late ’60’s, ’70, who had 
multiple failures.  She keeps saying she thinks she is not for depression but anxious, but 
she presents as depressed meaning she fires the pancake, no energy, and you know. But 
she does, she says I want you to treat my anxiety because is that is what is worries me, 
my panic, my agitation.  And she’s been a sort of a, an enabler all her life and you know 
she gave energy away, and so it’s more of the behavioral really than it is medical.  But 
she, but then she doesn’t want to look at that.  (laughing) So she wants a magic pill right. 
So, she has now many, many, many medications and she’s been in and out of day 
treatment programs, hospitalization.  And so, we find the advantage to this so try 
Trintellix her because it does so many things you know lifts the depression, calms the 
anxiety, and helps with focus and concentration and help with the energy like needing the 
cognition and then feeling more energized.  So, I convinced her to try that, and she 
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started doing a little better, but then she became more activated and agitated as we were 
going up on the dose, and this has been her history that she did this thing whenever the 
doctor would go up on the dose she would get more agitated.  So, what we did, we got 
her test done for gene test done and I had the test results the day that she called us that 
she was getting more agitated.  And so, we opened the gene testing, and in her case, she 
needs a lower dose.  And so, instead of increasing the dose, I just said break that pill in 
half, and just take that a half a pill, and then let’s see what happens.  And she really kind 
of got stable after that time minimal medication now.” In this situation, the clinician was 
able to change the dosing of medication to improve the patient’s outcome. 
Depressive Disorders 
 Some clinicians found it helpful to look at allele changes in patients with 
depression to guide their clinical decision-making. One clinician stated, “Evidence pretty 
strongly suggest and supports depression tests to make sure that they will respond to 
SSRIs.  But they have that short form not to use an SSRI and to go with an SNRI, SNRA, 
you know something different.  So, I think we’re starting to see more evidence for some 
of the other allele changes for some of the pharmacodynamics things, but not enough 
duplication in the studies yet to definitively say yes, these results, means you should do 
this.  I think right now outside of depression it’s more of a loose guideline that might 
steer you in the right direction, but it does not necessarily mean do “x”, do “y”.” 
Similarly, another clinician stated, “But she had been tried on two or three different 
SSRIs for depression and anxiety since a teenager. And I said yeah let’s do some genetic 
testing with you and I did and it turned out she had two short genes on her serotonin 
transporter. So, you know it was typically indicating more, might expect a poor response 
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to serotonin medication so which kind of proved why she had not done well on the three 
SSRIs and I put her on Wellbutrin.”  
 Another clinician found the pharmacogenetic testing was helpful but more helpful 
in conjunction with other therapies. This clinician stated, “I have one patient who 
basically had failed everything and every combination of everything and I’ve been trying 
for years to help her with her depression. And she was like the first person I did use the 
test on because she was suffering so much and had such bad response from all these 
things we tried and it still didn’t. So, you know using the medication from the green 
category, she still does not go into remission. So, it wasn’t actually until, it wasn’t 
actually, until I really bumped her up out of the normal dose range and combined it with a 
typical and Alpha-Stim. I started using Alpha-Stim for, and that's the combination of all 
the above and it would just be enough to tip her into remission.”  
Schizophrenia 
 Several clinicians reported that pharmacogenetic testing often confirmed why 
medications were ineffective in patients with Schizophrenia. One clinician stated, “I find 
especially with my patients with schizophrenia that the test just confirms while nothing is 
worthwhile, nothing is working, because they have a full or partial deletion of the 
dopamine 2 receptor.  And so, then it usually, especially they have that history of failing 
multiple antipsychotics that as we know most of them have the high affinity for D2.  
Then I will try to give them to where it’s something that has like Clozapine or Prolixin 
that has higher affinity at D1 and D4.  You know, I try to think about a different way to 
approach their illness.” 
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 Another clinician stated, “I have found it helpful recently, well I had a girl get the 
testing because we’re trying to see which neuroleptic medicine for her schizophrenia.  
She was having side effects and it came back and said that basically that she was the 
slower metabolizer and she was more likely to get side effects and needed lower dosage. 
Good to know because cause when I start these meds, I started the lowest possible dose.  
And she went to the hospital, they increased it a little bit she was having side effects so 
we had to drop it back down, so we’re going to increase it very slowly considering that I 
know the genetic testing.  I actually send a copy to the hospital with her but I don’t think 
they looked at it.” The clinician reported that the patient tolerated the medication at lower 
doses and found that it was not helpful when the clinicians in the hospital did not take the 
test into consideration.  
 An additional clinician stated, “So, her primary care provider was prescribing 
simvastatin for her and so her diagnosis that I was treating her for was paranoid 
schizophrenia. And she is a very complicated patient in that she is a polio survivor and 
she’s in a wheelchair every time she comes to see me. Although I think she can stand 
because she’s does use her legs to move the wheelchair. Anyway, she has a history of 
LSD usage. And she was telling me that every evening about 6 o'clock in the evening, 
she would start hallucinating, visual hallucinations, like she was on an LSD trip. With 
flashing lights and it was very uncomfortable for her. So, she’s been on all kinds of 
medication. She was on Haldol which I really didn’t want to see her stay on because I 
was beginning to learn about the neurotoxicity of Haldol. So, I did the pharmacogenetic 
testing to find out which meds would be best for her because I was intending to switch 
her meds. So, when I discovered that she doesn’t metabolize simvastatin properly and the 
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debris from the metabolism collects in her tissue and it can clog up her kidneys. I notified 
her primary care provider and immediately took her off of the Simvastatin. And within 
weeks, the hallucinations she had everyday stopped. So, I believe they came from the 
abnormal metabolism of the Simvastatin. So, with this one test, I can determine if there 
any abnormalities in her genetic structure that would affect the medications for those 
different diagnoses.” Clinicians found pharmacogenetic testing to be helpful to reduce 
side effects and increase tolerability of medications in patients with Schizophrenia. 
Clinician Recommendations 
 Clinicians in the sample found the test to beneficial in clinical practice. Despite 
the benefits of the test, several clinicians suggested several recommendations to improve 
the practicability of the test. Clinicians recommended test affordability, test expansion, 
online access, patient education materials, and a more efficient ordering process and 
turnaround for test results.  
Test Affordability 
 Most clinicians found that most government payers provide adequate coverage for 
pharmacogenetic testing. However, commercial insurance or cash payers may not be able 
to afford the pharmacogenetic testing according to most clinicians in this sample. Cost is 
a major barrier for this patient population. Although most pharmacogenetic testing 
companies provide an income-based sliding scale, some patients are still not able to 
afford the test.  
 Clinicians recommended an expansion of insurance coverage for the test. One 
clinician stated, “The insurance company policies that has stipulations on why they will 
pay for it and why they won't pay for it. I think personalized medicine is the best thing 
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yet. I know there are some inpatient facilities on the east coast that do this testing on 
every single patient in their facility. That’s part of the intake procedure. And I think that’s 
terrific. I think every provider should be able to gather this information at the beginning 
of every treatment, every course of treatment for every patient because it’s actually 
personalized the treatment plan to that specific person.”  
 Many clinicians found pharmacogenetic testing to be beneficial in guiding 
treatment decisions, however, some insurance companies will only cover 
pharmacogenetic testing if a person a specific diagnosis. For example, one clinician 
reported that insurance companies will only cover testing if the patient is taking Plavix. 
While another clinician found that certain insurance companies required a diagnosis of 
Depression before they would cover the test. Clinicians agreed that the test provided 
information specific to a person’s DNA not just a diagnosis or medication. Therefore, 
clinicians recommended an expansion of insurance coverage for persons with mental 
illness.  
 Overall, most clinicians concurred that costs should be “more clear and upfront” 
for the patients. One clinician stated, “I wish it would be more affordable for everybody. 
The price would be more reasonable, maybe in the future it could, you know.”  
Test Expansion 
 Clinicians had several recommendations including more information on old and 
new medications, efficacy of medications, side effects of medications, augmentation of 
medication, and inclusion of natural/homeopathic medications. First of all, clinicians 
recommended an expansion of medications listed on the report. For example, one 
clinician stated, “I think the company is a little slow on adding to the list of the drugs that 
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they test for new drugs.  They are drugs that have been out for pretty good while that they 
don’t test for and then there’s a few old drugs that I use, that they don’t test for. It took a 
long time for Trintellix. Then there’s a couple that still aren’t on their two and then I used 
some old drugs like Serzone and they don’t test for that.”  The clinicians did not believe 
that the list of medications was adequate and took too long to add newer medications. 
Some clinicians found it time consuming when certain medications were not listed in the 
report. For example, a clinician reported, “you can still, mean, kind of sort of extrapolate 
the information because you can find out what the pharmacodynamics and 
pharmacokinetics and most of those drugs are and guesstimate based on the testing, 
although I still like to have it on the reports and not have to jump through the hoops.”  
 Several clinicians recommended a more specific, detailed report to narrow down 
medication choices. One clinician stated, “I guess just, which medication would be the 
first one to try or which one would be, if there was any way to tell the ones that work 
better than one of the others that are listed as being genetically appropriate for use of the 
clients.”  Some clinicians perceived the report as being “too vague”. For example, 
another clinician stated, “It will say here like the serum level maybe too high.  Lower 
doses may be required.  Okay, well that’s fine, but you don’t know if that like slightly 
lower dose or half the dose, I mean it’s still kind of vague. Right, so maybe just more 
specific instead of just generally saying, yeah. Yeah, but again that might be all that they 
know from the science. I mean but it doesn’t say anything specific, like reduce the dose at 
50 percent.  It might see that with somebody with renal failure or something that we have 
our general guidelines, but it’s just kind of vague.” 
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 In addition, clinicians recommended a greater efficacy in treatment response to 
specific illnesses. For example, one clinician stated, “I just don’t think, I don’t think the 
efficacy is by any means has to, anything over 70% has been my experience.”  Some 
clinicians found that few patients continued to have significant reactions to medications 
that were listed in the “green column”. For example, one clinician started a patient on 
Elavil and her lips began to swell. The clinician stated, “She was like, are you trying to 
kill me. She was really at the end of her ropes. She’s had, so much, go wrong…So, it’s 
still bad for…Yeah, I thought that was going to be the you know, I was going to ride in 
on the white horse to save the day, but I was just one more person that tried to kill her.”   
Clinicians stated that this has not happened often and most of the time the test is helpful. 
However, the clinicians reported that they would like to see some advances in the test to 
rule out if someone is more prone to having an allergic reaction or a significant adverse 
effect from the medication.  
 Clinicians recommended more information on medication augmentation and 
interactions between medications. One clinician stated, “So many of our patients don’t 
come in on one drug you know they all come in around six different medications with all 
their interactions. So, it doesn’t help me with interactions or combos you know I wish it 
would you know maybe that's the next step for the gene. I wish it would show like yeah it 
would show okay this combination and they all come in on Wellbutrin and Zoloft.”  
 Additional clinicians recommended that the pharmacogenetic test included a more 
natural, integrative approach to treatment. One clinician stated, “I just wish that they had 
a way to direct us in the use of more natural things.  And just, that is actually my 
preference is more integrative care and natural care.  So, we don’t have the FDA, we got 
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the clinical studies or a test to tell us, which of all the over the counter products you know 
as a best magnesium or best millennium, or the best anything we don’t have that. We do a 
direct patient to the National Institute of health, you know and to other places where they 
have some database on those things.  But I wish they were a test that would tell me 
something like that that would be awesome.”  
 Additional clinicians recommend a more detailed information on specific genes. 
One clinician stated, “For example with the methylfolate enzymes, to have a significant 
size paragraph that explains what is this enzyme, and why are we testing for it, what is 
the difference in treatment if somebody just has a very minor error.” Some clinicians 
recommended a more scientific report to understand the clinical importance of the 
specific genes.  
 Overall, clinicians recommended a more detailed, specific report to look at the 
whole picture. Some clinicians preferred more knowledge on the integrative, natural 
approach to treatment including over the counter supplements. Lastly, clinicians believed 
the test was helpful in medication treatment decisions but the test is not “100% fool 
proof” at this point. Clinicians suggests that we will know more about the efficacy of the 
test as more people begin to use the test at a macro level.  
Online Access 
 Several clinicians recommended online access of the report for patients and 
providers. For example, one clinician stated, “And I think if patients could potentially 
have online access to that information or easier access to that information might be more 
beneficial for the patients so that they could share it with the others more easily. But then 
again that increases access to that information from other, corporations or places that 
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could misuse information.” Many providers agreed that the test results would be 
beneficial to other healthcare providers including primary care providers, emergency 
providers, and pain specialists. Although many providers give a copy of the report to the 
patient, clinicians believed electronic access may be more beneficial.  
 In addition, several clinicians recommended the pharmacogenetic test results to be 
linked to their electronic medical records. One clinician stated, “Everything that they're 
doing, that can be electronic is helpful. This is not electronically test. There’s no HL7 
interface so it’s just a document, I don't really know if it would help to have an HL7 for 
it, although it would be easier to handle…in terms of the medical record it might be nice 
to have it in the data part of the EMRs” Similarly, another clinician stated, “What would 
be really nice, would be, if it interfaced with the EHR. Which it doesn’t do, so that it 
could pull all the demographics the F codes and everything, you know, all the 
requirements to order the test.” Overall, clinicians believed it would be more conducive 
to be able to connect the report with the electronic medical records. 
Patient Education 
 Most clinicians recommended education material for patients in “layman’s 
terms”. Many clinicians give a copy of the pharmacogenetic test report to the patient but 
feel that it is difficult for the patient to understand. One clinician recommended, “A 
patient education sheet or something in layman’s terms to help them understand it more 
when they take the copy of the report home and study it.”  Similarly, another clinician 
stated, “I would say maybe put it in more simple terms.  The reports when we give it to 
the patients to say like an algorithm of what treatment plan they should be on.  And avoid 
this, stay away from this, increase this, decrease this, if you choose to use it.” Additional 
 114 
 
clinicians recommended more educational materials for patients and a compact report for 
patients.  
 Another clinician stated, “I would like to see a clear explanation to them about 
what the results actually mean.”  Other clinicians recommended an explanation on a 
brochure to provide specific details on what the test is going to show, and specify that the 
test does not specifically show the “most efficacious medicine or diagnosis”.  Most 
clinicians reported that they do not have any literature about pharmacogenetic testing in 
their clinics to give to patients. However, clinicians did report that they believe there is 
some information on the website but many clinicians report they have not utilized this 
resource. 
 Many clinicians commented on the length of the pharmacogenetic testing report. 
One clinician stated, “But the one thing that I probably would like to see changed 
eventually is with the report itself it’s so lengthy. And for the patients it could be a little 
overwhelming if they really try to look into all the different P450 information and being 
are you an ultra-rapid metabolizer or slow metabolizer. You know, it comes out like 17 
pages when it’s all said and done.” Most clinicians only discuss the highlights with the 
patient and do not discuss the different types of metabolizers.  
 Another recommendation by clinicians was to update the format of the report for 
patients. Clinicians reported the current nomenclature and format is confusing for 
patients. For example, one clinician stated, "One thing I don’t like about the test is it 
categorizes medications just kind of arbitrarily, like it will say that Prozac is an 
antidepressant.  It only has it in on the antidepressant page.  And that’s one thing Prozac 
is used for but its’ also used for lots of other things. It’s approved for anxiety and things 
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like that, the same thing for the antipsychotics.  I mean they’re used to augment, they’re 
used for bipolar but they just put them on the antipsychotic page.  So, if you’re trying to 
augment an antidepressant with Abilify and the patient sees it only on the antipsychotic 
page, they’re going to say why you giving me an antipsychotic for my depression, I’m 
not psychotic. You know just lump all those together because clinically when I’m going 
through that, I have to explain to patients. Now this is antipsychotics and you're one of 
these medicines and you are not psychotic. These are also medicines we use to treat…and 
I have to go through that spill just to remind them I'm not saying you’re psychotic. I'm 
not saying you have schizophrenia, because I'm, you know because you’re already on one 
of these medicines by me or from another doctor, that's not what we mean. Maybe you 
have irritability associated with autism maybe you have bipolar illness maybe you have 
to treatment resistant depression. These medicines are all used for that too not just for 
psychotic symptoms.  So, to me I feel like that’s a little bit confusing and maybe you get 
maybe a little bit of a negative connotation perhaps.”  
 The same clinician also mentioned that Propranolol is listed on the test report as 
an anxiolytic but it is classified as a beta blocker medication. Although Propranolol is 
used to treat anxiety, it is also used to treat hypertension.  Clinicians report this is 
confusing for patients when medications are used to treat more than one illness and the 
medication is only listed under one classification of medications on the report. Overall, 
clinicians would like to have more education materials available for the patient including 
a report that is simple for patients to understand.  
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Time Restraints 
 Many clinicians recommended a more efficient order process. Most clinicians 
agreed that the collection of the sample was easy and only took 30 second but the 
paperwork was time consuming. One clinician stated, “I can do it pretty quickly, but 
when people aren’t used to ordering it it’s like it’s kind of cumbersome.” Another 
clinician stated, wish we could do a little bit less paperwork with it, you know, the test 
itself takes 30 seconds and then swab 30 seconds and then paperwork takes a while, you 
know, this whole pile of work that needs to fill in and all that.”  Similarly, another 
clinician stated, “the site is a little complicated we have an MA in our clinic who really 
struggles with trying to put in all the information and it just, you have to do things just so 
in order to you know order the test. So, it’s a little temperamental you know, the ordering 
process.” Some clinicians reported that they do not have a nurse or medical assistant to 
help them with the ordering process of the test which can be very time consuming. 
Clinicians recommended a less cumbersome process for ordering the test.  
 In reference to results, some clinicians recommended a quicker turnaround time to 
receive the results. One clinician stated, “I think it would be great to swab and who 
knows what the mechanism will be and instantly have the results.  And you know 
sometimes I will say you know let’s just wait till tomorrow. And I’ll start the medication 
instead of let me start you off with something and then end up changing it in 24 hours if 
the results indicate that.  So, I think it will be great if it was kind of an immediately read 
type of test and I think we’ll get there.” For some clinicians it can take two to three weeks 
to obtain results from the test which delays treatment.  
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 Additional clinicians requested an alternative method to be able to use DNA from 
previous years to develop an updated report when new medications are added to the 
medication profile list rather than having to repeat the entire test again. One clinician 
stated, “But I wish if I could go back in without having to repeat the test and just have 
them you know run the DNA that I collected a few years ago with the new testing. That 
would be really convenient rather than if I, you know, if I wanted to do test for mood 
stabilizers. Then I have to have the patient come back in do the whole procedure again, 
versus, just adding a test on the sample that we've already submitted that would be really 
nice.” 
 Overall, clinicians recommended less paperwork and a more efficient way to 
order the test. In addition, clinicians desired a more rapid turnaround time for test results 
so that treatment could be initiated sooner. Lastly, clinicians recommended an updated 
report when new medications are added to the medication profile without repeating the 
entire test.  
Policy Concerns and Challenges 
 In regards to pharmacogenetic testing, several policy concerns and challenges are 
evident and should not be overlooked. Several challenges with insurance coverage were 
identified. These challenges included restrictions on pharmacogenetic testing and 
medication coverages. Another challenge identified was the lack of formal education for 
clinicians regarding pharmacogenetic testing. This section discussed the impact of these 
challenges on pharmacogenetic testing in clinical practice. 
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Insurance coverage 
 Many clinicians reported significant policy concerns with insurance coverage for 
pharmacogenetic testing and medication coverage. Clinicians reported that insurance 
companies put restrictions on specific diagnostic codes and would only cover testing for 
persons with a specific diagnosis. In addition, clinicians have found that insurance plans 
require them to prescribe first line medications despite the pharmacogenetic testing 
results.  
 For example, one clinician reported that it would not be useful to conduct the test 
on a medication naïve patient if the insurance will require them to try a certain 
medication first. This clinician stated, “The first-line treatments that their Medicaid plan 
covers, we still have to start with trying them.” Clinicians found that medication coverage 
by insurance companies was not influenced by the results of the pharmacogenetic testing.  
 Many clinicians found that some of the brand medications or off-label use 
medications suggested by the pharmacogenetic testing were not covered by insurance 
plans. Insurance plans either required a generic medication as first-line or a recorded 
number of failed trials before they would cover a medication that might be suggested by 
the test. For example, clinicians reported that the patient may be a normal metabolizer for 
a newer medication that the insurance company will not cover although the insurance 
company paid for the pharmacogenetic testing. In addition, some insurance companies 
may not cover medications that are off-label uses such as Pristiq or Lamictal in children.  
 These policy concerns were significant barriers for clinicians. Many clinicians 
believed that if the test results revealed that a person would benefit from a non-formulary 
medication, then insurance should take this into consideration when providing medication 
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coverage. In addition, clinicians professed that insurance companies should expand 
pharmacogenetic testing coverage beyond one specific diagnostic code or diagnosis.  
Formal Education for Clinicians 
 Most clinicians reported that they did not receive any formal training on 
pharmacogenetic testing. In this sample, the majority of clinicians received training from 
pharmacogenetic testing representatives. Clinicians reported that the training consisted 
mostly of how to obtain the DNA sample and order the test. The clinicians stated that the 
pharmacogenetic testing companies provided resources for providers including 
geneticists and Pharm D’s who are available by phone to answer any questions about the 
test and how it works. However, many clinicians in this sample reported that they have 
not utilized these resources.   
Some clinicians learned about pharmacogenetic testing from peers and by seeking 
training on their own through training institutions and online research on the topic. 
Clinicians in the sample found additional educational courses on pharmacogenetic testing 
at the University of Colorado, Stanford University, and the Clinical Pharmacogenomics 
Implementation Consortium. Few clinicians in the sample learned about pharmacogenetic 
testing during graduate school. One clinician stated, “It’s not in either clinical track 
curricula, nor is it in MD curricula or PA.  You know, people know that it exists, but they 
don’t know what it means.  Like just because things are on my panel, it does not 
necessarily mean that the evidence is there for it to be clinical actionable.  But of course, 
if you listen to the vendor, they will tell you, oh absolutely it is.  But the reality is that the 
evidence they say not quite be there yet. It certainly wasn’t taught to me in school, in my 
university, it absolutely should have been.”  Similarly, another clinician stated, “you 
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know the pathways, the Cytochrome P450 pathways, I don’t even hardly even understand 
that.  You know I mean I get what that means but I mean outside of any confusion, or 
concerns, or anything about that how I’m interpreting except I’ll even call pharmacists 
who I have that my personal contact or I call the or just call the number that’s on the gene 
test thing there is the number on the results of the test that you can call to talk to a Pharm 
D and talk to them about how to interpret the test or apply the information of the test.” 
 Overall, there is a need for extensive and formal educational training for 
clinicians who are utilizing pharmacogenetic testing in clinical practice. While some 
clinicians in the sample have a broader understanding of pharmacogenetic testing, other 
clinicians believe that their knowledge is limited.  The implementation of 
pharmacogenetic training in nursing and medical curricula may benefit future clinicians 
who will be utilizing pharmacogenetic testing in clinical practice. 
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Chapter V 
INTERPRETATIONS, CONCLUSIONS, AND RECOMMENDATION 
 This study’s aim was to evaluate mental health clinicians’ perceived knowledge 
regarding pharmacogenetic testing, their attitude, receptivity towards, and confidence in 
pharmacogenetic testing, and how pharmacogenetic testing is being implemented in 
outpatient mental health clinics. This study compared experiences of 28 mental health 
clinicians regarding experience with pharmacogenetic testing. The relevant themes of this 
qualitative descriptive analysis focused on the perceptions of pharmacogenetic testing, 
impact on clinical decision-making, associated concerns of pharmacogenetic testing, 
knowledge gaps among clinicians, and policy challenges. This chapter discusses the 
summary of findings, implications for research, practice and policy, unique attributes of 
the study, and limitations of the study.  
 
Summary of Findings 
Clinicians in this study have been using pharmacogenetic testing from two 
months to twelve years in outpatient mental health clinics to guide treatment decisions. 
Many of the participants utilized pharmacogenetic testing to guide dosing and medication 
selection to decrease the risk of side effects and increase tolerability of psychotropic 
medications. Clinicians found that patients are receptive to pharmacogenetic testing and 
have an overall good understanding of the test. Despite the receptivity and benefits of 
pharmacogenetic testing, clinicians have received minimal formal training on such testing 
in clinical practice. However, clinicians continue to use the test and have positive results. 
Some clinicians stated that the test is not “100% fool proof” but they have found it 
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helpful in the majority of cases. Clinicians identified some downsides and risks of the 
test, as well as, some recommendations to improve the practicability of the test. 
A Tool for Prescribing 
Clinician’s views about pharmacogenetic testing were similar to previous studies 
that discussed how to implement pharmacogenetic testing in clinical practice (Dunbar et 
al., 2012; Walden, et al. 2015). Pharmacogenetic testing was viewed as an additional tool 
to assist with medication selection and dosing of medications. In contrast to previous 
studies, clinicians in this sample obtained the DNA sample using a buccal swab or saliva 
specimen, whereas, previous studies obtained a blood sample, (Dunbar et al., 2012; 
Walden et al., 2015). Clinicians in this study utilized a variety of pharmacogenetic testing 
companies including: Genesight, Genomind, Millennium, Ingenetics, Ventari, and 
IDgenetics. Most clinicians chose a company based on input from colleagues and 
recommended choosing a testing company with a good reputation and evidence based 
literature. 
Initial Exposure and Training 
Clinician’s exposure to pharmacogenetic testing was very limited. Most clinicians 
in this study initially learned about pharmacogenetic testing through testing company 
representatives and colleagues.  In contrast, previous literature suggests that the primary 
source of education for psychiatrists was attending a continuing education course or 
reviewing the current medical literature. However, many clinicians in this sample 
reported that no formal education was provided.  Similarly, to previous literature, few 
clinicians learned about pharmacogenetic testing their training programs of study. Hoop 
et al. (2010) found that 61% of psychiatry faculty and residents (n=67) received none to 
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minimal training on pharmacogenetic testing. Some clinicians in this sample sought 
additional training at conferences and seminars through educational institutions.  
Factors Considered in Decision-Making 
 Clinicians identified cost as a major factor in deciding to order pharmacogenetic 
testing for patients with mental illness. Although most government payers cover the cost 
of the test, many patients with commercial insurance or no insurance could not afford the 
test. Clinicians in this sample were less likely to order pharmacogenetic testing for 
patients with commercial insurance or cash payers. Similarly, previous literature 
concurred that the cost of the test was a potential disadvantage of pharmacogenetic 
testing (Dunbar et al., 2012).  
 Another factor in decision-making identified by clinicians included the benefits of 
the test. Clinicians in this sample found the test lessened patient’s fears and anxieties 
about medications, validated patient’s experiences, and improved tolerability and 
adherence of medications. Similarly, additional researchers found that mental health 
clinicians believed pharmacogenetic testing improved trust and rapport with patients and 
clinicians, improved medication adherence, and predicted fewer side effects from 
medications (Dunbar et al., 2012). 
 Another major deciding factor that influenced clinicians to order the test included 
if the patient was medication naïve or had experienced multiple medication failures. Most 
clinicians in this sample were more likely to order pharmacogenetic testing for patients 
who had multiple medication failures or adverse effects from medications. Similarly, 
mental health clinicians in previous studies perceived the test to be useful in patients who 
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may have an increased sensitivity to medications to improve medication tolerance 
(Dunbar et al., 2012; Hoop et al., 2010).  
 The severity of illness was a significant factor in decision-making for ordering 
pharmacogenetic testing. Clinicians were more likely to order testing in patients with 
more severe or treatment resistant mental illness. Most clinicians were not likely to order 
pharmacogenetic testing for patients who were stable and doing well on their current 
medication regimen. 
Impact on Clinical Decision-Making 
The impact of pharmacogenetic testing on clinical decision-making matches with 
several studies that discuss the perceived usefulness of pharmacogenetic testing. 
Clinicians in this study found that pharmacogenetic testing provided reassurance to the 
clinician and patient. Clinicians believed that the test often provided confirmation that 
they were “on the right track”. Similarly, a previous study found that mental health 
clinicians perceived pharmacogenetic testing confirmed prior clinical decisions and 
judgement regarding medication dosing and clinicians (Dunbar et al., 2012).  In addition, 
clinicians were more confident in their decisions (Dunbar et al., 2012). Clinicians found 
that pharmacogenetic guided treatment gave them permission to go beyond their normal 
choice of treatment in certain situations especially in the adolescent population. 
Clinicians in this study found pharmacogenetic testing to be influential in 
understanding how the metabolizing of medications can impact patients who have been 
resistant to treatment. Similarly, previous researchers found that mental health clinicians 
found pharmacogenetic testing to be effective in patients who were “abnormal 
metabolizers” of medications and at risk of adverse effects of medications even at lower 
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doses (Dunbar et al, 2012).  Clinicians in this sample found pharmacogenetic testing to 
reduce trial and error and provides a more scientific approach to treating patients with 
mental illness. 
Although the majority of clinicians found the test to have a positive impact on 
clinical decision-making, approximately 25% of participants believed the 
pharmacogenetic guided treatment did not have a significant impact on clinical decision-
making. Clinicians found that results may indicate that the patient does not have any 
metabolism abnormalities with medication or the medication indicated is not clinically 
relevant to the patient’s symptoms. Clinicians perceived that the test was not “100% fool 
proof”. Some clinicians believed that the test was accurate 90% of the time while others 
believed it was accurate only 50% of the time. 
Shared Decision-Making 
 Shared decision-making was defined by clinicians as open dialogue with the 
patient and clinician and giving patient treatment options along with the clinician’s 
clinical judgement. Most clinicians practiced this model of care with or without the 
pharmacogenetic guided treatment. Correspondingly, to previous literature, clinicians 
believed that shared decision-making and pharmacogenetic guided treatment built a level 
of trust and rapport with patients (Dunbar et al., 2012). 
Populations Who Do Not Benefit from Pharmacogenetic Testing 
 Several populations were identified in the study that clinicians perceived would 
not benefit from pharmacogenetic testing. Clinicians believed that patients who were 
currently stable on medications, medication naïve, preferred alternative treatment, or had 
cognitive distortions or a personality disorder would have limited benefits from 
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pharmacogenetic testing.  Previous research is limited in this area, however, psychiatry 
faculty and residents believed that pharmacogenetic testing should only be tested on 
patients with clinical decision-making capacity (Hoop et al., 2010).  
Risks and Downsides 
 Clinicians acknowledged several risks or downsides to pharmacogenetic testing. 
A major risk or downside for some clinicians was a lack of clinical evidence for patients 
who have other mental illnesses besides depression. Researchers have found 
pharmacogenetic testing to demonstrate clinical effectiveness as a guide to medication 
selection in two open-label cohort studies and one randomized, double-blind controlled 
trial (Hall-Flavin et al., 2012; Hall-Flavin et al., 2013; Winner et al., 2013). In all three 
studies, participants who received pharmacogenetic testing experienced a greater 
improvement in depressive symptoms when compared to the unguided group (Hall-
Flavin et al., 2012; Hall-Flavin et al., 2013; Winner, Carhart, Altar, Allen, & Dechairo, 
2013). Further research is needed to explore the impact of pharmacogenetic testing on 
clinical outcomes in other patient populations since these studies are limited to patients 
with depressive symptoms only.   
 Another downside acknowledged by clinicians was whether the test reports were 
too simplistic or too scientific. Some clinicians preferred a more detailed scientific report 
while others preferred a simplified “genetics for dummies” report. Some clinicians prefer 
to look at a summary of the genes whereas, other clinicians prefer to look at the “green, 
yellow, red” columns in the report to determine medication selection.  
 Medication and cost barriers were recognized as major downsides by clinicians. 
Many clinicians found that insurance would not cover off-label medications, medical 
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foods such as Deplin or L-methylfolate, or some brand name medications even if the 
medications are indicated clinically and by the pharmacogenetic test results. Another 
major downside was the cost of the test. Clinicians found that government payers cover 
the cost of the test 100%, however, commercial payers and cash payers may not be able 
to afford the test. Some testing companies provide an income-based sliding scale, but 
clinicians are concerned that some patients may not be able to afford the sliding scale 
rates. In addition, clinicians reported that some patients are receiving an “explanation of 
benefits” and interpret this as a bill causing undue stress on the patient. 
Lastly, some clinicians are concerned about the misinterpretation or misuse of the 
data obtained from the test. Clinicians believe there is a risk of patients or clinicians 
misinterpreting the test results. In addition, there are some ethical concerns such as DNA 
being misused by insurance companies or a patient may internalize the results negatively. 
Similarly, psychiatry faculty and residents believed that pharmacogenetic testing could 
potentially cause a patient psychological distress (Dunbar et al., 2012). 
Patient’s Perception of Pharmacogenetic Testing 
The majority of clinicians in this sample perceived patient “buy in”, perceived 
effectiveness, and patient education to be significant factors in the patient’s perception of 
pharmacogenetic testing. Many clinicians believed that the patient’s level of 
understanding was greatly affected by how the provider educates the patient. Clinicians 
reported spending up to one hour discussing the test and results. Most clinicians 
recommended providing a simple explanation of results depending on the patient’s 
education level.  
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Overall, patients were receptive of the test. Clinicians found the test provided 
hope, trust, and confidence among patients. The patients were favorable to having 
something that is on paper and more scientific than the traditional trial and error 
approach. Clinicians also believed that patient “buy in” was a significant factor in clinical 
outcomes. Some clinicians perceived that the test had a “placebo effect” which may 
improve clinical outcomes.  
Application of Test Results Among Clinicians 
Pharmacogenetic testing is not unique to this study, but other researchers have 
shown the perceived usefulness of such testing in among patients with mental illness. 
Previous researchers have focused on the impact of pharmacogenetic testing among 
patients with depressive disorders but limited studies exist on clinical outcomes of other 
psychiatric disorders. Clinicians in this sample found the test applicable to several 
different patient populations including Adolescents, Autism and Non-verbal patients, 
Addiction Disorders, ADHD, Anxiety Disorders, Depressive Disorders, and 
Schizophrenia. Clinicians found pharmacogenetic testing to be helpful to reduce side 
effects and improve medication tolerability among these patients. Additional studies are 
needed to further explore clinical outcomes in these patient populations.   
Clinician Recommendations 
 Clinicians recommended test affordability, test expansion, online access of 
results, patient education materials, and more efficient ordering process of 
pharmacogenetic testing. Overall, clinicians concurred that the cost of pharmacogenetic 
testing should be more affordable to patients. Clinicians also recommended expanding 
the test to include more of the older and newer medications, along with more details 
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about interactions among drug combinations used in clinical practice. Some clinicians 
requested an integration of natural/homeopathic medications into the report. Several 
clinicians recommended linking the report with electronic medical records.  
Another major concern for several clinicians was the format and nomenclature of 
the report. Most clinicians preferred more educational materials for patients that explains 
the results in “layman’s terms”. Many clinicians believe the report is confusing for 
patients and difficult for them to understand.  
Lastly, clinicians recommended a more efficient ordering process and faster 
turnaround time for results. Similarly, previous researchers found that psychiatry faculty 
and residents also experienced delays in testing results and staff had poor accessibility in 
test forms (Dunbar et al., 2012). On average, clinicians received test results within two to 
three weeks, however, some clinicians received results as soon as forty-eight hours.  In 
addition, clinicians found the ordering process to be tedious and time consuming.  
Policy Concerns and Challenges 
 A major policy concern and challenge identified by clinicians was insurance 
coverage for the test and medications. Clinicians reported restrictions from insurance 
companies that only provided coverage for pharmacogenetic testing for specific 
diagnostic codes. Although insurance companies paid for the pharmacogenetic test, 
clinicians reported that insurance plans would only cover medications on their formulary 
despite findings on the pharmacogenetic test.  
 Another significant policy concern and challenge among clinicians was the lack 
of formal education for clinicians. Most clinicians have not received formal training on 
pharmacogenetics but have learned from pharmacogenetic testing representative and 
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colleagues. There is a need to implement pharmacogenetic education in medical and 
nursing curricula along with expanding continuing education options for clinicians.  
Implications for Practice 
Pharmacogenetic testing can be useful for the mental health clinician in 
understanding and avoiding drug-drug interactions when prescribing medications (Kung 
& Xiaofan, 2010).  A person’s metabolizer status can determine the pathway medications 
are metabolized to determine dosage and reduce the medication combinations used in the 
treatment of mental illness. Pharmacogenetic testing can prevent unnecessary, ineffective 
treatment (Cascorbi & Tyndale, 2014). The clinical implications of this study are: 1) To 
enhance other clinicians’ level of confidence and acceptance regarding pharmacogenetic 
testing in clinical practice, 2) Assist mental health clinicians to determine the type of 
patients that may benefit from pharmacogenetic testing, 3) Inform clinicians how 
pharmacogenetic testing is being used in clinical decision-making regarding medication 
management, and 4) Increase clinicians’ knowledge of how pharmacogenetic is being 
used to educate families and patients.  
Confidence and Acceptance of Pharmacogenetic Testing 
 Previous research confirms that the majority of clinicians welcome 
pharmacogenetic testing and believe that patients would benefit from such testing 
(Thompson, Hamilton, & Hippman, 2015). However, the implementation of 
pharmacogenetic in mental health has been sluggish despite the support of 
pharmacogenetic testing in the literature (Burke, Love, Jones, & Fife, 2016). Burke et al., 
(2016) suggests that some clinicians may be unaware that such testing is available or 
unaware of the applicability of pharmacogenetic testing among patients with mental 
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illness (Squassina et al., 2010). However, patients expect clinicians to be knowledgeable 
about pharmacogenetic testing (Squassina et al., 2010).  This study can be used to inform 
other mental health clinicians about the usefulness of pharmacogenetic testing which may 
increase clinicians’ knowledge level and confidence level, therefore, increasing the 
number of clinicians using such testing in mental health practice. Focusing on the 
clinicians’ experience with pharmacogenetic testing will provide a unique opportunity for 
the results to be understood by other clinicians which is pertinent to the acceptance of the 
intervention (Sullivan-Bolyai et al., 2005).   
Identify Target Populations  
 This study will help clinicians identify the type of patients who may benefit from 
pharmacogenetic testing in clinical practice. Although pharmacogenetic testing provides 
gene-drug information for various psychotropic medications, most studies have been 
focused on adults with depression (Hall-Flavin et al., 2012; Hall-Flavin, et al., 2013; 
Winner, Carhart, Altar, Allen, & Dechairo, 2013).  However, these tests are being used to 
guide treatment in patients with anxiety, schizophrenia, mood disorders, and other mental 
illnesses in clinics. This study provides clinicians with information on who is being tested 
and the perceptions of clinician’s regarding what population may or may not benefit from 
such testing. This will help the clinician identify target populations in their clinical 
setting.  
Medication Planning and Monitoring  
 Traditional treatment for patients with mental illness has focused on a trial and 
error approach to prescribing medications (Langman & Dasgupta, 2012). A trial and error 
approach increase the risk of side effects, being over medicated, or the medication being 
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ineffective to treat symptoms (Mrazek, 2010).  In pharmacogenetic testing, genetic 
factors are being used by clinicians to guide medication selection and dosing of 
medication to improve patient outcomes (National Institutes of Health: National Human 
Genome Research Institute, 2014).  
 Researchers have found that a patient’s metabolizer status can be determined 
according to certain enzymes (Black, O’Kane, & Mrazek, 2007). Patients may be ultra-
rapid metabolizers (greater ability to metabolize medications), extensive metabolizers 
(normal ability to metabolize medications), intermediate metabolizers (less ability to 
metabolize medications), or poor metabolizers (no ability to metabolize medications) of a 
certain medication – requiring very different doses or perhaps different medications-- 
depending on their genetic expression of a particular enzyme (Black et al., 2007).  For 
example, patients identified as poor metabolizers are at increased for side effects, while 
an ultra-rapid metabolizer is unlikely to respond to standard doses of medications. 
Pharmacogenetic testing guided treatment can improve the accuracy of medication 
responses and decrease the risk of side effects (Mrazek, 2010). Researchers found that 
ultra-rapid metabolizers had multiple medication failures and untreated symptoms and 
were at greater risk of completed suicide than those who died from natural causes 
(Zackrisson, Lindblom, & Ahlner, 2010).  
 This study provides clinicians with information on how mental health clinicians 
are using pharmacogenetic testing to guide medication selection and monitor among 
patients with mental illness. A greater understanding of how to use pharmacogenetic 
testing in medication management may reduce polypharmacy which is common in mental 
health prescribing (Laje, 2013). Since there are no current guidelines, understanding the 
 133 
 
clinicians’ decision-making process guided by pharmacogenetic testing can be valuable 
for clinicians to adapt these findings into clinical practice.  
Patient and Family Education  
 This study may help clinicians translate pharmacogenetic testing into practice by 
understand how clinicians are using pharmacogenetic testing to educate patients and 
families regarding their treatment plan. This information can be beneficial to clinicians 
who are beginning to implement pharmacogenetic testing in practice. Often patients do 
not understand medical terminology and clinicians are responsible for promoting patient 
understanding of pharmacogenetic testing results (Haga, Mills, & Bosworth, 2014).  
Terms such as “ultra-rapid metabolizer” may be confusing to a patient or family member 
and lead to unwarranted anxiety (Haga et al., 2014). In addition, understanding how 
clinicians are communicating test results may assist in the development of educational 
aids for patients and families regarding pharmacogenetic testing. 
Implications for Policy 
Currently, there are no clinical guidelines using pharmacogenetic testing in 
mental health practice (Quinones et al., 2014).  However, a large majority of clinicians 
believe that pharmacogenetic testing will become the standard of care (Walden et al., 
2015). The study provides insight on clinicians’ deciding factors when determining who 
receives treatment, as well as, how the test is interpreted and applied in the clinical 
setting. This information may provide a foundation for developing pharmacogenetic 
testing guidelines and policy in mental health clinical practice. 
 In addition, this study provides a foundation for educational programs for 
clinicians using pharmacogenetic testing. Research consistently shows clinicians 
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typically report limited knowledge or understanding of pharmacogenetic testing (Dodson, 
2011). This study explores clinicians’ knowledge base regarding pharmacogenetic testing 
and provides insight regarding gaps in clinicians’ knowledge. This information can help 
guide curriculum development on pharmacogenetics in medical and nursing programs. In 
addition, the information can be used to develop continuing education programs for 
current clinicians to learn about the implications of pharmacogenetic testing in clinical 
practice. 
 Lastly, this study provides information for payers regarding insurance coverage 
for pharmacogenetic testing and medication coverage. Clinicians reported inconsistencies 
among payers and medication coverage. For example, payers who provide coverage for 
pharmacogenetic testing continue to have limited coverage for non-formulary 
medications despite testing results. In addition, some payers have limited coverage for 
pharmacogenetic testing to specific diagnostic codes which may not be applicable to all 
patients who would benefit from pharmacogenetic testing.  
Implications for Research 
Further research is needed to explore patient outcomes from pharmacogenetic 
testing interventions (Fackler & McGuire, 2009). This study provides a foundation for 
future studies on the impact of pharmacogenetic testing on medication adherence and 
tolerability, medication efficacy, and shared decision-making. Additional studies are 
needed to explore the implementation of pharmacogenetic testing and patient outcomes in 
mental health clinics (Burke et al., 2016). 
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Medication Adherence and Tolerability 
The tolerability and effectiveness of psychotropic medications is highly variable. 
Approximately 60% of patients do not respond completely to antidepressants and 30% do 
not respond at all (Crisafulli, Fabbri, Porcelli, Drago, SPina, & Deronchi, 2011). 
Similarly, 74% of patients being treated for Schizophrenia discontinued medications due 
to side effects and ineffectiveness (Lieberman, Stroup, McEvoy, Swartz, Rosenheck, 
Perkins, & Hsiao, 2005). Due to genetic factors, patients may vary widely in how they 
respond to mental health medications. For example, genetic factors contribute to 
approximately 50% of antidepressant responses (Crissafull et al., 2011). Patients 
metabolize antidepressants at vastly different rates and can experience different responses 
to the same drug (Dalen, Dahl, Ruiz, Nordin, & Bertilsson, 1998; Lohaff & Ferraro, 
2010). 
 This study provides a foundation for future studies to determine if 
pharmacogenetic guided treatment may be a key factor in medication adherence and 
tolerability. Researchers found that pharmacogenetic guided treatment improved 
depressive symptoms among adult patients with depression (Hall-Flavin et al., 2012; 
Hall-Flavin, et al., 2013; Winner et al., 2013).  In a retrospective study, researchers found 
patients who received pharmacogenetic guided treatment were significantly more 
adherent to medications when compared to the standard treatment group (Fagerness et al., 
2014).  Limited studies have been conducted on the effects of pharmacogenetic guided 
treatment on medication adherence among patients with mental illness.  
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Medication Efficacy 
  Patients who are characterized as rapid ultra-metabolizer are at the greatest risk 
for experiencing reduced efficacy in medications (Mrazek, 2010). Future research is 
needed to assess effects of pharmacogenetic testing on medication efficacy among 
patients with mental illness. Previous studies have focused primarily on patients with 
depression. In two open label cohort studies and one randomized controlled trial, 
participants who received pharmacogenetic guided treatment had improvement in 
depressive symptoms when compared to the standard treatment group (Hall-Flavin et al., 
2012; Hall-Flavin, et al., 2013; Winner et al., 2013). Additional randomized controlled 
trials are needed to further explore medication efficacy among patients with mental 
illness. This study provides a foundation for exploring patient outcomes related to 
pharmacogenetic guided treatment and medication efficacy.  
Shared Decision-Making 
 Historically, the primary approach to decision making was a paternalistic 
approach where providers assumed the dominant role in treatment decisions by making a 
decision based on clinical findings and scientific evidence (Charles et al., 1999). 
Researchers have found that most patients with mental illness want to be involved in 
decision making regarding their treatment including medications and hospitalizations 
(Hamann, Cohen, Leucht, Busch, & Kissling, 2005). Pharmacogenetic testing is one way 
clinicians can implement shared decision-making among patients with mental illness in 
the selection of medications and adherence medications. 
 Previous research has focused on exploring clinician and patient views on shared-
decision making or patient outcomes (Patel, Schnall, Little, Lewis-Fernandez, & Pincus, 
 137 
 
2013; Stevenson, Barry, Britten, Barber, & Bradley, 2000). Researchers have found 
shared decision- making to be effective in improving medication adherence, greater 
patient satisfaction with care, and improvement in psychiatric symptoms among patients 
with mental illness (Hamann et al., 2006; Loh et al., 2007, Van Korf et al., 2003; Van Os 
et al., 2004). However, to the author’s knowledge, no studies have been conducted on 
how pharmacogenetic guided treatment has been integrated into shared decision-making. 
This study explored how clinicians are implementing shared decision-making in 
treatment decision using pharmacogenetic guided treatment. This study provides a 
foundation for future studies on shared decision-making in this population.   
Unique Attributes of the Study 
 This qualitative descriptive study evaluated mental health clinicians’ perceived 
knowledge regarding pharmacogenetic testing, their attitude, receptivity towards, and 
confidence in pharmacogenetic testing, and how pharmacogenetic testing is being 
implemented to support precision medicine in outpatient clinics. Few studies have 
examined clinicians’ knowledge and perceptions of pharmacogenetic testing or how such 
testing is being implemented into clinical practice. In addition, previous studies have 
focused primarily on psychiatrists, psychiatrist residents, and undergraduate medicine 
students. This study includes Advanced Practice Nurses (Nurse Practitioners and Clinical 
Nurse Specialists), Medical Doctors (Psychiatrists), and Physician Assistants who are 
utilizing pharmacogenetic testing in outpatient mental health clinics. Advanced Practice 
Nurses are at the forefront of patient care and can evaluate genetic factors associated with 
medication dosing and tolerability (Davies, Conley, & Puskar, 2010). In addition, this 
study focused on how clinicians are actively implementing pharmacogenetic testing in 
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practice. Previous studies have primarily focused on healthcare professionals with limited 
or no experience with pharmacogenetic testing (Walden et al., 2015).  Lastly, the timing 
of this study, during a time when pharmacogenetic testing is becoming more prevalent, 
may have captured some unique characteristics of how to implement such testing in 
clinical practice, as well as, provide a foundation to develop clinical guidelines for 
pharmacogenetic testing.  
Limitations 
 Several important limitations emerged from this study. First of all, the 
generalizability of study findings may be limited by the study population primarily from 
the Southeast region (SC, NC, and GA; n=21) of the United States; however other 
participants were from a variety of locations across the United States including AZ, MO, 
MN, OR, IN, and HI. Future studies are needed to use a more diverse sample of clinicians 
including clinical psychologists and other mental health prescribing clinicians. The 
sample in this study consisted of Nurse Practitioners, Clinical Nurse Specialists, 
Psychiatrists, and Physician Assistants. In addition, this study focused on mental health 
clinicians working in outpatient mental health clinics. Future studies may need to include 
clinicians at inpatient and residential mental health facilities. Lastly, the sample size in 
this study was limited to twenty-eight mental health clinicians. Sampling in qualitative 
research can be challenging since the access population may not represent the full target 
population and sample sizes may be significantly smaller (Polit & Beck, 2016). 
 Despite these limitations, this study has clinical significance. Few research studies 
have examined clinicians’ knowledge, perception, and implementation of 
pharmacogenetic testing in mental health clinics. Previous studies have focused on 
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healthcare professionals with limited or no experience with pharmacogenetic testing or 
academic centers (Hoop et al., 2010; Walden et al., 2015).  Most importantly, this study 
will lead to future research to support shared decision-making around pharmacogenetic 
testing, medication adherence and tolerability, and setting guidelines for pharmacogenetic 
testing in mental health clinics. Findings from this study, in conjunction with future 
studies, will provide the foundation to develop clinical guidelines for pharmacogenetic 
testing and the implementation of pharmacogenetic testing into medical and nursing 
curriculum.  
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Appendix A 
Demographic Form 
 
1. What is your Professional Title?  
 M.D. or D.O. 
 Nurse Practitioner 
 Clinical Nurse Specialist 
 Clinical Psychologist 
 Physician Assistant 
 Other___________________ 
 
2. What is your current age? _____________ 
 
3. What is your gender?  ____ Male  ____Female 
 
4. How long have you been practicing as a mental health clinician?   
 
________Months ________Years 
 
5. How long have you been using pharmacogenetic testing in clinical practice?  
 
 ________Months ________Years 
 
6. What type of pharmacogenetic test are you using in clinical practice?  
 
__________________________________________________________ 
 
7. What is the approximate number of patients who receive pharmacogenetic testing in 
your  
 
clinical practice? ____________ 
 
8. What is the average number of patients that see in your practice per month?  
____________ 
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Appendix B 
Semi-structured Interview Guide 
 
Clinician: Can you tell me about your experiences with pharmacogenetics testing? 
Follow up questions/probes as needed:  
• How does the test work? How did you first learn about this type of test?  
• What kind of training, if any, have you had that prepared you to use this kind of 
test in practice? How did you decide to use, or not use pharmacogenetics testing 
in your practice?  
• Has pharmacogenetics testing changed your practice?  If so, how?  
• Who does the test benefit? How has the test been beneficial? 
• How often are you using pharmacogenetics testing with your patients? 
• How do you think your patients perceive pharmacogenetics testing? How well do 
you think patients understand the test?  
• How do you decide who will receive pharmacogenetics testing? When do you 
introduce it into your clinical workflow? 
• How do you include shared decision-making when making clinical decisions 
guided by the pharmacogenetics testing?   
• What type of patients who would not benefit from this test?  What patients would 
you not recommend it for? 
• Are there risks to pharmacogenetics testing? Downsides? Do you have concerns 
about this practice? 
• If you could change anything about the test, what would you change?  
• Any other questions I should have asked you? 
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